HIV Seropositivity: Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).HIV Seroprevalence: Studies of the number of cases where human immunodeficiency virus (HIV) is present in a specific population at a designated time. The presence in a given individual is determined by the finding of HIV antibodies in the serum (HIV SEROPOSITIVITY).HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).Substance Abuse, Intravenous: Abuse, overuse, or misuse of a substance by its injection into a vein.Sexual Behavior: Sexual activities of humans.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Seroepidemiologic Studies: EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Chlamydophila pneumoniae: A species of CHLAMYDOPHILA that causes acute respiratory infection, especially atypical pneumonia, in humans, horses, and koalas.Chlamydophila Infections: Infections with bacteria of the genus CHLAMYDOPHILA.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Serologic Tests: Diagnostic procedures involving immunoglobulin reactions.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.HIV Seronegativity: Immune status consisting of non-production of HIV antibodies, as determined by various serological tests.Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.Helicobacter pylori: A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405).Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.Toxocariasis: Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.Antibodies, Protozoan: Immunoglobulins produced in a response to PROTOZOAN ANTIGENS.Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.Toxoplasmosis: The acquired form of infection by Toxoplasma gondii in animals and man.Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.Cross-Sectional Studies: Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.Toxocara: A genus of ascarid nematodes commonly parasitic in the intestines of cats and dogs.Herpesvirus 2, Human: A species of SIMPLEXVIRUS associated with genital infections (HERPES GENITALIS). It is transmitted by sexual intercourse and close personal contact.AIDS Serodiagnosis: Immunologic tests for identification of HIV (HTLV-III/LAV) antibodies. They include assays for HIV SEROPOSITIVITY and HIV SERONEGATIVITY that have been developed for screening persons carrying the viral antibody from patients with overt symptoms of AIDS or AIDS-RELATED COMPLEX.HIV-1: The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.Blood DonorsHepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.Neospora: A genus of protozoan parasites of the subclass COCCIDIA. Its species are parasitic in dogs, cattle, goats, and sheep, among others. N. caninum, a species that mainly infects dogs, is intracellular in neural and other cells of the body, multiplies by endodyogeny, has no parasitophorous vacuole, and has numerous rhoptries. It is known to cause lesions in many tissues, especially the brain and spinal cord as well as abortion in the expectant mother.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Papillomavirus Infections: Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.Rural Population: The inhabitants of rural areas or of small towns classified as rural.Syphilis: A contagious venereal disease caused by the spirochete TREPONEMA PALLIDUM.Herpes Genitalis: Infection of the genitals (GENITALIA) with HERPES SIMPLEX VIRUS in either the males or the females.Cytomegalovirus: A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.Toxoplasma: A genus of protozoa parasitic to birds and mammals. T. gondii is one of the most common infectious pathogenic animal parasites of man.Immunoglobulin A: Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions.BrazilHomosexuality: The sexual attraction or relationship between members of the same SEX.

*  High Uptake of Postpartum Hormonal Contraception Among HIV-1... : Sexually...
Sexual and reproductive life of women informed of their HIV seropositivity: A prospective cohort study in Burkina Faso. J ... Study Design: HIV-1-infected pregnant women were followed prospectively in a perinatal HIV-1 transmission study. Participants ... In 2001, the United Nations General Assembly special session on HIV/AIDS set the goal to reduce the proportion of HIV-1- ... The majority (72%) of HIV-1-infected women followed in this prevention of mother-to-child HIV-1 transmission cohort initiated
http://journals.lww.com/stdjournal/Fulltext/2007/01000/High_Uptake_of_Postpartum_Hormonal_Contraception.5.aspx
*  The Development of PROQOL-HIV: An International Instrument... : JAIDS Journal...
... is an important outcome in HIV/AIDS infection and ... was rumination and obsessive thinking about HIV seropositivity ... In conclusion, PROQOL-HIV shows much promise as an HRQL instrument reflective of the themes that dominate the experience of HIV ... WHOQOL-HIV further includes domains that are rather generic and not specifically linked to HIV, such as home environment, ... PROQOL-HIV is a novel multidimensional HIV-specific HRQL instrument that strives to be sensitive to sociocultural context,
http://journals.lww.com/jaids/Fulltext/2012/04150/The_Development_of_PROQOL_HIV___An_International.12.aspx
*  The Case Against Infant Circumcision: Binga Men Refuse Circumcision and have...
Seropositivity is the state of having blood serum that tests positive for a given pathogen, especially HIV.. Binga recorded the ... So women in these tribes have lower HIV because their men are choosing condoms, why isn't this highlighted?. Binga had low ... "But the many people in the fishing camps are from different areas and this could worsen the HIV situation in the district." ... The area recorded the lowest seropositivity rates in the province. Now why isn't this highlight, as more effective than
http://mondofown.blogspot.com.au/2015/05/binga-men-refuse-circumcision-and-have.html
*  The Case Against Infant Circumcision
Seropositivity is the state of having blood serum that tests positive for a given pathogen, especially HIV.. Binga recorded the ... live longer have lower hiv/sti's, and view the intact penis as healthy and normal, its left looking like just tribal mythology. ... So women in these tribes have lower HIV because their men are choosing condoms, why isn't this highlighted?. Binga had low ... "But the many people in the fishing camps are from different areas and this could worsen the HIV situation in the ...
http://mondofown.blogspot.com.au
*  The influence of immunological markers to susceptibility to HIV, HBV, and HCV...
Additionally to HIV, HBV/HCV double-infection influenced only the percentages of CD4+ T cells and the seropositivity to these ... We aimed to describe whether IL-10 polymorphisms influence HIV, HBV, and HCV susceptibility and how exposure and seropositivity ... polümorfismid mõjutavad HIV-i nakatumist ja kuidas HIV-i koosesinemine HBV ja HCV-ga ning süstiv narkomaania mõjutavad T ... Inimese immuunpuudulikkuse viirus (HIV), B-hepatiidi viirus (HBV) ja C-hepatiidi viirus (HCV) põhjustavad nii ...
http://dspace.ut.ee/handle/10062/55696?locale-attribute=de
*  Plus it
Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC: Risk of diabetes in HIV infected veterans pre- and post-HAART ... prevalence of HCV infection in diabetic patients is not related to the main risk factors associated with HCV seropositivity (17 ... Ageing, obesity, family history of diabetes, African-American origin, and HIV coinfection are recognized influencing factors ... The effect of HAART and HCV infection on the developement of hyperglycemia among HIV-infected persons. J Acquir ...
http://care.diabetesjournals.org/content/29/5/1140
*  11/27/13 ~ HCV Research and News
HIV Education HIV medications HIV Prevention HIV Screening HIV Vaccine Trials HIV/AIDS HIV/AIDS Awareness HIV/AIDS Research HIV ... In Italy the estimated prevalence of anti-Hepatitis C virus (HCV) antibody seropositivity in the general population is 2,9%, ... In an 11-month period, HIV testing of new inmates in North Carolina found that 1.45% of them had HIV, according to David Wohl, ... Transmission HIV/HBV Coinfection HIV/HCV Coinfection IDU IDX184 IDX19368 IDX19370 IDX20963 IDX21437 IDX21459 IDX2963
http://hepatitiscresearchandnewsupdates.blogspot.com/2013_11_27_archive.html
*  Profile of HIV Seropositive Patients - Tabular View - ClinicalTrials.gov
... Skip to Main Content. A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies:. Advanced Search. Help. Studies by Topic. Glossary. Find Studies. Basic Search. Advanced Search. See Studies by Topic. See Studies on Map. How to Search. How to Use Search Results. How to Find Results of Studies. How to Read a Study Record. About Clinical Studies. Learn About Clinical Studies. Other Sites About Clinical Studies. Glossary of Common Site Terms. Submit Studies. Why Should I Register and Submit Results. FDAAA 801 Requirements. How to Apply for an Account. How to Register Your Study. How to Edit Your Study Record. How to Submit Your Results. Frequently Asked Questions. Support Materials. Training Materials. Resources. Selected Publications. Clinical Alerts and Advisories. RSS Feeds. Trends, Charts, and Maps. Downloading Content for Analysis. About This Site. ClinicalTrials.gov Background. About the Results Database. History, Policies, and Laws. Media/Press ...
https://clinicaltrials.gov/ct2/show/record/NCT00981279
*  Results for: Subject:HIV Seropositivity | EthicShare Community
Adult ; Female ; HIV Seropositivity ; Health Knowledge, Attitudes, Practice ; Humans ; Prejudice ; South Africa ; Women s Health ;. Adult ; Female ; HIV Seropositivity ; Health Knowledge, Attitudes, Practice ; Humans ; Prejudice ; South Africa ; Women s Health ;. Attitude to Health ; Culture ; Female ; HIV Infections ; HIV Seropositivity ; Homosexuality ; Humans ; Male ; Power Psychology ; Prejudice ; Risk Factors ; Sexual Behavior ; Social Environment ; Socioeconomic Factors ; Substance-Related Disorders ; World Health ;. Attitude to Health ; Culture ; Female ; HIV Infections ; HIV Seropositivity ; Homosexuality ; Humans ; Male ; Power Psychology ; Prejudice ; Risk Factors ; Sexual Behavior ; Social Environment ; Socioeconomic Factors ; Substance-Related Disorders ; World Health ;. Adult ; Breast Feeding ; Child ; Child Nutrition Sciences ; Child, Preschool ; Diet ; Dietary Supplements ; Food, Fortified ; HIV Seropositivity ...
https://ethicshare.org/publications/(subject_parametric:"HIV Seropositivity")?filters=ss_cck_field_type:"Teaching/Conference Materials"&subject=HIV Seropositivity&sc=advanced
*  U Patil - ResearchGate
Preliminary observations on lymphocyte subpopulations in HIV seropositive HIV seronegative tuberculosis patients in Pune, India. ABSTRACT: CD4 and CD8 lymphocyte counts were determined in 59 HIV seropositive and 41 HIV seronegative newly diagnosed tuberculosis patients in Pune. There were significant differences in the CD4 counts and CD4/CD8 ratios between HIV seropositive and HIV seronegative tuberculosis patients. Majority of the HIV seropositive patients had a CD4 count less than 500 cells/cu.mm, whereas among the HIV seronegative patients, majority had a CD4 count more than 500 cells/cu.mm. In HIV seropositive patients with extrapulmonary and pulmonary tuberculosis, the CD4 counts were lower than in those who had only pulmonary or extrapulmonary tuberculosis. There was no significant differences in the CD8 counts between HIV seropositive and HIV seronegative tuberculosis patients, except for patients with pulmonary cavity, where ...
http://researchgate.net/researcher/7487080_U_Patil
*  JAMA Network | JAMA | Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in
Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration. View Large | Save Figure | Download Slide .ppt | View in Article Context. Table Graphic Jump Location Table 1.—Descriptive Statistics of 536 HIV Seroconverters Seen at Different Calendar Periods in the Multicenter AIDS Cohort Study From 1984 to 1997*. + View Large | Save Table | Download Slide .ppt | View in Article Context. Table Graphic Jump Location Table 2.—Drug Therapy and Health Care Use in 4 Calendar Periods by HIV Seroconverters in the Multicenter AIDS Cohort Study From 1984 to 1997*. + View Large | Save Table | Download Slide .ppt | View in Article Context. View Large | Save Figure | Download Slide .ppt | View in Article Context. View Large | Save Figure | Download Slide .ppt | View in Article Context. Table Graphic Jump Location Table 3.—Antiretroviral Therapy and Relative AIDS-Free and Survival Times by Calendar Periods*. + View Large | Save Table | Download Slide ...
http://jama.jamanetwork.com/article.aspx?articleid=188126
*  HIV-positive people
... thumb|right|400px. 'World map of travel and residence restrictions against people with HIV/AIDS'. 'Legend:'. 'HIV-positive people' are people who have the human immunodeficiency virus HIV, the agent of the currently incurable disease AIDS. Over the years of coping with the stigma and discrimination that accompany the diagnosis in most societies, a large number of support groups have been formed. In these groups, the term most often applied to people who are HIV-positive is "People Living With HIV/AIDS". This is often abbreviated as "PLWHA" or "PLHIV". Recently, "People Living Positively" has also been used. 1 The largest and oldest of the worldwide networks of people living with HIV is the Global Network of People Living With HIV/AIDS GNP+, which has affiliate networks on every continent. According to estimates by WHO and UNAIDS, 34.2 million people were living with HIV at the end of 2011. http://www.who.int/features/qa/71/en/index.html ...
https://en.wikipedia.org/wiki/HIV-positive_people
*  HIV Seroconversion : Illness, Time, Syndrome
... HIV Symptoms. HIV Seroconversion It is essential to understand the process of HIV seroconversion and the symptoms are the chief elements in early detection and treatment of HIV infection. Seroconversion illustrates the process of the body's immune response to either immunization or infection. When the antigen i.e. virus, bacteria, toxins etc. are detected by an immune system, antibodies are formed by the immune system in response to HIV. Forming detectable antibodies to a particular antigen is described as seroconversion. When HIV antibodies are created by an immune system, a person is considered as HIV seropositive. HIV Seroconversion: Acute Infection Phase A person may experience acute phase or primary phase of HIV infection after two weeks to three months after the infection. This is the period when seroconversion occurs. In this phase, the body identifies the existence of HIV and response to it by creating the antibodies. It is ...
http://hivsymptomsonline.com/hiv-seroconversion.html
*  Nutritional recovery in HIV-infected and HIV-uninfected children with severe acute malnutrition -
... UCL Discovery. UCL Discovery. UCL home » Library Services » Electronic resources » UCL Discovery Enter your search terms. UCL Theses. About UCL Discovery. Nutritional recovery in HIV-infected and HIV-uninfected children with severe acute malnutrition. Nutritional recovery in HIV-infected and HIV-uninfected children with severe acute malnutrition. This study explores nutritional recovery in HIV-infected and HIV-uninfected children during inpatient nutrition rehabilitation and 4 months of follow-up.Design: Prospective cohort study.Setting: Lilongwe district, Malawi.Main outcome measures: Weight gain, anthropometrics.Results: In our sample of 454 children with severe acute malnutrition SAM, 17.4% n = 79 of children were HIV infected. Among the HIV-infected children, 35.4% 28/79 died, compared with 10.4% 39/375 in HIV-uninfected children p 0.001. All children who survived achieved nutritional recovery 85% weight for height and no oedema, ...
http://discovery.ucl.ac.uk/125133/
*  Asymptomatic HIV infection Medical Information
... All Consumer Professional Pill ID Interactions News FDA Alerts Approvals Pipeline Clinical Trials Care Notes Encyclopedia Dictionary Natural Products. Asymptomatic HIV infection. Asymptomatic HIV infection Asymptomatic HIV infection is a phase of chronic infection with human immunodeficiency virus HIV during which there are no symptoms of HIV infection. Causes of Asymptomatic HIV infection. Asymptomatic HIV infection is phase in which the immune system in someone with HIV slowly deteriorates, but the person has no symptoms. Asymptomatic HIV infection Symptoms. Asymptomatic HIV means a person does not have symptoms typically seen in people with HIV. A diagnosis of HIV infection is based on results from blood tests, including the HIV antibody test ELISA. Treatment of Asymptomatic HIV infection. When a person without symptoms of AIDs should receive therapy remains controversial. Those who do not have symptoms ...
http://drugs.com/enc/asymptomatic-hiv-infection.html
*  Bacteremia in Human Immunodeficiency Virus-infected Children... : The Pediatric Infectious Diseas
... e Journal. Advertisement. Enter your Email address:. Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. The Pediatric Infectious Disease Journal Wolters Kluwer Health Logo. Subscribe. Search Jobs. Saved Searches. Recent Searches. You currently have no recent searches. Login. Register. Activate Subscription. eTOC. Help. All Issues Current Issue Issue Displayed. Advanced Search. Home Currently selected. Current Issue. Previous Issues. Published Ahead-of-Print. Collections. For Authors. Information for Authors. Language Editing Services. Journal Info. About the Journal. Editorial Board. Affiliated Societies. Advertising. Open Access. Subscription Services. Reprints. Rights and Permissions. Mobile. New Features. iPad App. Home. October 2011 - Volume 30 - Issue 10. Bacteremia in Human Immunodeficiency ...
http://journals.lww.com/pidj/Abstract/2011/10000/Bacteremia_in_Human_Immunodeficiency.23.aspx
*  SCHERING-PLOUGH PRESENTS CLINICAL DATA ON CCR5 RECEPTOR ANTAGONIST AT 9TH CONFERENCE ON RETROVIRUSES
... AND OPPORTUNISTIC INFECTIONS. Conference Reports for NATAP. 9th Conference on Retroviruses and Opportunistic Infections   Seattle, Washington, February, 2002. Back  . SCHERING-PLOUGH PRESENTS CLINICAL DATA ON CCR5 RECEPTOR ANTAGONIST AT 9TH CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS. Following yesterday's oral presentation by a researcher from Schering Plough, Mark Laughlin, about their entry inhibitor for HIV, Schering issued this statement which I feel you'd like to read. Schering-Plough Research Institute today presented preliminary clinical data on its CCR5 receptor antagonist, a novel therapeutic approach in the treatment of HIV infection, at the 9th Conference on Retroviruses and Opportunistic Infections in Seattle. In an oral presentation at the conference's opening session on new antiretroviral agents, Mark M. Laughlin, M.D., director, clinical pharmacology, Schering-Plough Research Institute, presented clinical results showing a direct antiviral effect in ...
http://natap.org/2002/9retro/day2.htm
*  Infectious Disease Clinics of North America Journal Impact Factor & Description - ResearchGate
Infectious Disease Clinics of North America Journal Impact Factor Description - ResearchGate. Infectious Disease Clinics of North America INFECT DIS CLIN N AM Publisher: WB Saunders Journal description Each issue of Infectious Disease Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Infectious Disease Clinics website. Other titles Infectious disease clinics of North America, Infectious disease clinics. Auwaerter Infectious Disease Clinics of North America 06/2015; 29 2. DOI:10.1016/S0891-5520 15 00034-3. Clostridium difficile Infection. Wilcox Infectious Disease Clinics of North America 03/2015; 29 1. DOI:10.1016/S0891-5520 15 00009-4. ABSTRACT: Clostridium difficile infection CDI is the most common cause of infectious health care-associated diarrhea and is a major burden to patients and the health care system. Copyright © 2015 Elsevier Inc. All rights reserved. Infectious Disease Clinics of North America 03/2015; 29 1 :123-134. ...
http://researchgate.net/journal/0891-5520_Infectious_Disease_Clinics_of_North_America
*  JAMA | Antiretroviral Treatment of Adult HIV Infection2012 Recommendations of the International A
JAMA. Antiretroviral Treatment of Adult HIV Infection2012 Recommendations of the International Antiviral Society–USA Panel. Sign in via Shibboleth. Create an Account. The JAMA Network. JAMA The Journal of the American Medical Association. JAMA Surgery. You've earned it free CME tokens, redeemable for CME Credits, have been added to your personal account courtesy of The JAMA Network and. Antiretroviral Treatment of Adult HIV Infection : 2012 Recommendations of the International Antiviral Society–USA Panel Melanie A. doi:10.1001/jama.2012.7961. • Sign in to your personal account • Institutional sign in: Athens. October 17, 2012 Treatment of Human Immunodeficiency Virus in Adults Tom A. • Sign in to your personal account • Institutional sign in: Athens. Return to: Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel. Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral ...
http://jama.jamanetwork.com/article.aspx?articleid=1221704&atab=7
*  Highlights of the 5th Conference on Retroviruses and Opportunistic Infections - TheBody.com
... Advertisement. 0 Email. Print-Friendly. Glossary. Editorial Highlights of the 5th Conference on Retroviruses and Opportunistic Infections What Are the Newest Developments in the Treatment of HIV. How Will These Advances Affect You. An Advocate for People Living With HIV Provides a Full Report By Dawn Averitt From San Francisco General Hospital. April 1998 A note from TheBody.com: The field of medicine is constantly evolving. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information. The Conference on Retroviruses and Opportunistic Infections, which attracts more than 3,000 experts on HIV disease from around the globe, has come to be regarded as the most important scientific meeting of the year for those involved in AIDS research. The particular strength of this annual meeting is that it brings together researchers who rarely venture outside their laboratories and office-based physicians who ...
http://thebody.com/content/art12708.html?nxtprv
*  The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug u
... sers: A long-term retrospective cohort study. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Eighty HIV-positive and 80 HIV-negative injection drug users included between 1980 and 1995 were matched according to age, gender, and duration of HCV infection and followed-up during 52 months. High serum HCV-RNA level was associated with low CD4-lymphocyte count P = .001. The progression to cirrhosis was accelerated in HIV-positive patients with low CD4 cell count RR = 4.06, P = .024 and in interferon-untreated patients RR = 4.76, P = .001, independently of age at HCV infection P = .001. In this retrospective cohort study, HIV coinfection worsened the outcome of chronic hepatitis C, increasing both serum HCV-RNA level and liver damage and decreasing sustained response to interferon therapy. 1 to compare the virologic and histologic characteristics of chronic hepatitis C in ...
http://natap.org/2001/hepc/121001_1.htm
*  Abacavir and Myocardial Infarction Risk: Additional Data
... The question of whether abacavir increases the risk of myocardial infarction MI initially arose with a study from the D:A:D cohort last year, followed by conflicting analyses from other studies see previous HMQ reports Abacavir and Didanosine Associated with Increased Risk of Myocardial Infarction and Abacavir and Risk of Myocardial Infarction: The SMART Study. A case-control study from the French Hospital Database found that current or recent abacavir use was associated with MI risk odds ratio: 1.97, but only for subjects who had been on abacavir 1 year in patients on abacavir >1 year, or in those with past use of abacavir, there was no statistically significant increased risk of MI. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal. In: Program and abstracts of the 16th Conference on Retroviruses and ...
http://hivinsite.ucsf.edu/insite?page=hmq-0905-06
*  Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibili
... ty for Interferon Treatment. Articles. Back  . Hepatitis C Virus and Human Immunodeficiency Virus Coinfection in an Urban Population: Low Eligibility for Interferon Treatment. One hundred eighty human immunodeficiency virus HIV and hepatitis C virus HCV coinfected patients were prospectively evaluated for suitability for interferon and ribavirin therapy. Of the 149 patients with chronic HCV infection who completed the evaluation, 44 30% were eligible for treatment and 105 70% were ineligible, with the main barriers being missed clinic visits, active psychiatric illness, active drug or alcohol use, decompensated liver disease, or medical illness.. These barriers persisted despite ongoing education regarding the seriousness of HCV disease and access to a designated psychiatrist and substance abuse programs ..... These data underscore the challenges that exist in treating HCV disease in an urban population of HCV- and HIV-coinfected patients. Of interest, 14% of the patients referred were ...
http://natap.org/2003/Jan/012403_2.htm
*  Meeting the Behavioural Data Collection Needs of National HIV/AIDS and STD Programmes (Implementing
Meeting the Behavioural Data Collection Needs of National HIV/AIDS and STD Programmes Implementing AIDS Prevention and Care Project - Joint United Nations Programme on HIV/AIDS - United States Agency for International Development, 1998, 41 p. Sustaining behavioural data collection over time. HOME HELP PREFERENCES. Search Titles Subjects Organizations. EXPAND TEXT. EXPAND CONTENTS. DETACH. NO HIGHLIGHTING. Meeting the Behavioural Data Collection Needs of National HIV/AIDS and STD Programmes Implementing AIDS Prevention and Care Project - Joint United Nations Programme on HIV/AIDS - United States Agency for International Development, 1998, 41 p. introduction... 1 Introduction. 2 Why track behaviour. 3 Linking behavioural data with HIV serosurveillance. 4 What is needed to understand and track behaviour. 5 Do people tell the truth about their sexual and drug-taking behaviour. 6 Recommended mix of data collection methods. 7 What next. 8 Sustaining behavioural data collection ...
http://nzdl.org/gsdlmod?e=d-00000-00---off-0aedl--00-0----0-10-0---0---0direct-10---4-------0-1l--11-en-50---20-help---00-0-1-00-0--4----0-0-11-10-0utfZz-8-00&a=d&c=aedl&cl=CL3.30&d=HASHb0ab7655d451df28d95d51.9
*  Asymptomatic HIV Infection Symptoms & Treatment, NE - CHI Health, Omaha
... Asymptomatic HIV infection Definition Asymptomatic HIV infection is a phase of chronic infection with human immunodeficiency virus HIV during which there are no symptoms of HIV infection. Causes Asymptomatic HIV infection is phase in which the immune system in someone with HIV slowly deteriorates, but the person has no symptoms. Symptoms Asymptomatic HIV means a person does not have symptoms typically seen in people with HIV. A diagnosis of HIV infection is based on results from blood tests, including the HIV antibody test ELISA. Possible Complications People with asymptomatic infection can progress to symptomatic HIV infection, develop opportunistic infections associated with HIV, and transmit HIV to other people. People at risk for HIV infection should have regular testing to ensure early diagnosis of this infection, as many treatment options are available. Treatment of human immunodeficiency virus ...
http://chihealth.com/body.cfm?id=3218&action=detail&AEArticleID=000682&AEProductID=Adam2004_117&AEProjectTypeIDURL=APT_1
*  PLOS ONE: Active Tuberculosis Is Associated with Worse Clinical Outcomes in HIV-Infected African Pat
... ients on Antiretroviral Therapy. Article-Level Metrics. Click through the PLOS taxonomy to find articles in your field. View. Sum of PLOS and PubMed Central page views and downloads. Open Access Peer-reviewed Research Article. Active Tuberculosis Is Associated with Worse Clinical Outcomes in HIV-Infected African Patients on Antiretroviral Therapy. Active Tuberculosis Is Associated with Worse Clinical Outcomes in HIV-Infected African Patients on Antiretroviral Therapy Abraham M. Published: January 2, 2013 DOI: 10.1371/journal.pone.0053022. Article. This cohort study utilized data from a large HIV treatment program in western Kenya to describe the impact of active tuberculosis TB on clinical outcomes among African patients on antiretroviral therapy ART. 2013 Active Tuberculosis Is Associated with Worse Clinical Outcomes in HIV-Infected African Patients on Antiretroviral Therapy. For purposes of this analysis, patients were categorized into 3 groups based on their CD4 cell count ...
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053022
*  Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study WIHS. Library. E-mail. Contact Us. HIV Center for Women and Children. Patient Care and Services. AIDS Education and Training Center. HIV/ID Seminar Series. NYS International Training Research Program NYS-ITRP. HIV Track / Medicine Residency Program. HIV Track / PA Program. Counseling. Supportive Counseling Services. Patient Care. Medical Support for Adults. Medical Support for Adolescents. WIHS. Treatment of HIV/AIDS. Women Specific. Other Community Services. Birnbaum, MD, MPH. Howard Crystal, MD. DeHovitz, MD, MPH. Howard Minkoff, MD. Yusuff, MD, MPH. Seminar Series. Employment. NYS International Training Research Program NYS-ITRP. STAR Health Center. HIV Center for Women and Children. Women's Interagency HIV Study WIHS Women's Interagency HIV Study WIHS Funded by the National Institutes of Health for over 20 years, the multicenter Women's Interagency HIV Study WIHS is the largest and longest-running study to ...
http://downstate.edu/hiv/WIHS.html
*  hivandhepatitis.com - CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction [VIDEO] | HIV P
hivandhepatitis.com - CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction. HIV Prevention. hivandhepatitis.com. HIV/AIDS HIV/AIDS Topics HIV Prevention. HIV Disease Progression. HIV Testing Diagnosis. Hepatitis B Hepatitis B Topics HBV Treatment. HBV Disease Progression. HBV Prevention. HBV Testing Diagnosis. HIV/Hepatitis Coinfection HIV/HBV Coinfection. HIV/AIDS HIV/AIDS Topics. HIV Prevention CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction. CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction Details Category: HIV Prevention. Long-awaited results from the VOICE trial of post-exposure prophylaxis PrEP for women in Africa, presented at the recent 20th Conference on Retroviruses and Opportunistic Infections CROI 2013 in Atlanta, was not able to show that daily oral tenofovir plus emtricitabine the drugs in Truvada could lower the risk of HIV ...
http://hivandhepatitis.com/hiv-aids/hiv-aids-topics/hiv-prevention/4049-croi-2013-womens-prep-trial-does-show-hiv-risk-reduction-video
*  hivandhepatitis.com - Pegylated Interferon May Maintain HIV Suppression and Reduce Viral DNA Integra
... tion. hivandhepatitis.com. HIV/AIDS HIV/AIDS Topics HIV Prevention. HIV Disease Progression. HIV Testing Diagnosis. Hepatitis B Hepatitis B Topics HBV Treatment. HBV Disease Progression. HBV Populations. HBV Prevention. HBV Testing Diagnosis. HIV/Hepatitis Coinfection HIV/HBV Coinfection. Search for a Cure Pegylated Interferon May Maintain HIV Suppression and Reduce Viral DNA Integration. Pegylated Interferon May Maintain HIV Suppression and Reduce Viral DNA Integration Details Category: Search for a Cure. Adding pegylated interferon alfa to antiretroviral therapy ART for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections CROI 2012 and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases. Results At 12 weeks, 9 of 20 participants 45% who stayed on ...
http://hivandhepatitis.com/hiv-treatment/hiv-cure/3859-pegylated-interferon-may-maintain-hiv-suppression-and-reduce-viral-dna-integratio
*  U.S. National HIV/AIDS Strategy Release Is Imminent - TheBody.com
u s national hiv aids strategy release is imminent thebody com print this page back to web version of article u s national hiv aids strategy release is imminent by olivia ford june finally the release of the u s s first ever national hiv aids strategy is almost upon us we re no longer talking months we re talking weeks said u s office of national aids policy director jeffrey crowley in a conference call with community members on june organizations across the u s are circling the wagons preparing to alert their constituencies about the strategy upon its release since back in the days when onap convened a dozen plus open meetings in different cities and communities across the u s in order to document what people had to say about what should be included in the nation s first national hiv aids strategy they ve attempted to keep the community abreast of what they re up to as far as developing the strategy updating their own blog and that of aids gov releasing a shiny report including ...
http://thebody.com/content/art57089.html?ts=pf
*  The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk - Full Text View - Clinical
... Trials.gov. Find Studies Study Record Detail. The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk This study has been completed. Sponsor: University of California, San Francisco Collaborator: GlaxoSmithKline Information provided by Responsible Party : University of California, San Francisco. ClinicalTrials.gov Identifier: NCT01333644 First received: March 1, 2011 Last updated: May 29, 2015 Last verified: May 2015 History of Changes. Just as these changes are thought be causally associated with heart disease in the very old,the investigators postulate that these changes will be associated with early heart disease in the untreated and perhaps treated HIV disease. HIV Infection Cardiovascular Disease Inflammation. Official Title: The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk. Further study details as provided by University of California, San Francisco:. HIV-Infection Treated HIV-infected individuals with an ...
https://clinicaltrials.gov/ct2/show/NCT01333644?term=" February 16, 2011":" March 18, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]&rank=5
*  POZ Exclusives
A Smart + Strong Site. ABOUT HIV/AIDS. What is HIV/AIDS. Back to home » POZ Exclusives March 31, 2010. March 25, 2010. March 16, 2010. March 10, 2010. March 09, 2010. HIV and the Brain: Part 2 At the 17th Conference on Retroviruses and Opportunistic Infections CROI in San Francisco David Evans speaks with Scott Letendre, MD, from the University of California in San Diego, about the relationship of HIV levels in the brain versus the blood, and what that might mean for treating HIV. New Treatments for HIV: Part 1 At the 17th Conference on Retroviruses and Opportunistic Infections CROI in San Francisco Tim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center in Los Angeles, about new HIV treatments including the drug blood level-booster, cobicistat, and the new integrase inhibitor, elvitegravir. New Treatments for HIV: Part 2 At the 17th Conference on Retroviruses and Opportunistic Infections CROI in San Francisco Tim Horn speaks with David ...
http://poz.com/archive/March_2010_401.shtml
*  .. Roundup: HIV Infection Rate Among Young Blacks “Alarming”, Abortion Returns
infection rate. · · · · ·. Abortion. Roundup: HIV Infection Rate Among Young Blacks “Alarming”, Abortion Returns to Spotlight. by Brady Swenson, RH Reality Check. September 12, 2008 - 10:00 am. CDC calls HIV infection rate for young black men “alarming”; Abortion has returned to the glaring spotlight of the 2008 election; Judge rejects abortion related anti-Obama group’s request for FEC injunction. · · · · ·. McCain, Obama Respond to New Numbers on HIV Infection Rate. by Julie Davids, CHAMP. August 5, 2008 - 7:00 am. In response to new numbers suggesting that the HIV infection rate in the U.S. is 40% higher than previously reported, Barack Obama called for a national HIV plan while John McCain failed to call for a national, coordinated strategy. · · · · ·.
http://rhrealitycheck.org/tag/infection-rate/
*  42 U.S. Code § 300ff–87a - National HIV/AIDS testing goal | LII / Legal Information Institute
Code § 300ff–87a - National HIV/AIDS testing goal. Code § 300ff–87a - National HIV/AIDS testing goal. a In general Not later than January 1, 2010, the Secretary shall establish a national HIV/AIDS testing goal of 5,000,000 tests for HIV/AIDS annually through federally-supported HIV/AIDS prevention, treatment, and care programs, including programs under this subchapter and other programs administered by the Centers for Disease Control and Prevention. 2 the total number of individuals tested through federally-supported and other HIV/AIDS prevention, treatment, and care programs in each State;. B through federally-supported and other HIV/AIDS prevention, treatment, and care programs, were diagnosed and referred into treatment and care during such period;. 5 the amount of funding the Secretary determines necessary to meet the annual testing goal in the following 12 months and the amount of Federal funding expended to meet the testing goal in the prior 12-month ...
https://law.cornell.edu/uscode/text/42/300ff-87a?quicktabs_8=0
*  Role of Therapeutic Drug Monitoring in Management of Pediatric HIV Infection | Pediatric ARV Guideli
Role of Therapeutic Drug Monitoring in Management of Pediatric HIV Infection. Search HIV/AIDS Drugs. Role of Therapeutic Drug Monitoring in Management of Pediatric HIV Infection. Adherence to Antiretroviral Therapy in HIV-Infected Children and Adolescents. Role of Therapeutic Drug Monitoring in Management of Pediatric HIV Infection. Please send your comments with the subject line Comments on Pediatric ARV Guidelines to ContactUs@aidsinfo.nih.gov by March 20, 2015. Evaluation of plasma concentrations of antiretroviral drugs is not required in the management of most pediatric patients with HIV, but should be considered in children on combination antiretroviral therapy in the following scenarios BII : Use of antiretroviral drugs with limited pharmacokinetic data and therapeutic experience in children e.g., for use of efavirenz in children aged 3 years and darunavir with once-daily dosing in children aged 12 years ; Significant drug-drug interactions and food-drug ...
https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/108/role-of-therapeutic-drug-monitoring-in-management-of-treatment-failure
*  Opinion : Implementing the National HIV/AIDS Strategy Across the United States - by Grant Colfax
... A Smart + Strong Site. POZ STORIES. POZ 100. NEWLY DIAGNOSED. ABOUT HIV/AIDS. What is HIV/AIDS. Newsfeed Treatment News POZ Exclusives Opinion Criminalization News Conference Coverage Global News World AIDS Day RSS Feeds. March 29, 2013 Implementing the National HIV/AIDS Strategy Across the United States. by Grant Colfax. Successful implementation of the National HIV/AIDS Strategy the Strategy requires ongoing collaboration among federal, state, and local governments and key non-governmental stakeholders. As part of our ongoing efforts to support Strategy implementation, ONAP is convening community discussions across the United States. moving people from an HIV diagnosis to care, treatment, and viral suppression The importance of the Affordable Care Act implementation for HIV care and prevention. At each meeting, state and local public health officials, representatives from community-based organizations, advocates, and other key stakeholders convene. ONAP and ...
http://poz.com/articles/grant_colfax_2676_23732.shtml?commentson=no
*  Antiretroviral Drugs May Halt HIV Spread in Heterosexuals --Doctors Lounge
... Search Symptoms. Medical Reference. Drugs. Back to Journal Articles Antiretroviral Drugs May Halt HIV Spread in Heterosexuals. Studies find that daily use may prevent HIV acquisition in unaffected heterosexuals. A daily oral dose of antiretroviral drugs used for the treatment of HIV infection may reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex, according to the results of a new U.S. Centers for Disease Control and Prevention study, the TDF2 study, along with the results of a separate trial Partners Pre-Exposure Prophylaxis study. WEDNESDAY, July 13 HealthDay News -- A daily oral dose of antiretroviral drugs used for the treatment of HIV infection may reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex, according to the results of a new U.S. Centers for Disease Control and Prevention study, the TDF2 study, along with the results of a separate trial Partners ...
http://doctorslounge.com/index.php/news/pb/21595
*  DermIS - HIV-Infection (information on the diagnosis)
dermis hiv infection information on the diagnosis doia pedoia information modules organisations user input info related doia same page in doia differential diagnoses infectious mononucleosis secondary lues chronic recurrent aphthae drug eruption related links search www google com for hiv infection search string by alphabet a b c d e f g h i j k l m n o p q r s t u v w x y z by localization hiv infection definition includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity through aids related complex arc to acquired immunodeficiency syndrome aids synonyms hiv infection umls hiv disease human immunodeficiency virus disease unspecified hiv disease unspecified human immunodeficiency virus disease hiv human immunodeficiency virus ...
http://dermis.net/dermisroot/en/11088/diagnosep.htm
*  UAB - SOM - Women's Interagency HIV Study. - Home
UAB - SOM - Women's Interagency HIV Study. Home About WIHS Participant Information Investigator Resources Getting to WIHS Contact Us. Enroll Today We are currently looking for 100 culturally and ethnically diversity women from Alabama and Mississippi who have HIV or at risk for HIV. If you choose to enroll in this study, you will be asked to provide data through:. Whether you are HIV positive or negative, the data you will provide will help increase scientific knowledge of HIV and its effect on the women's body. As an HIV negative participant, you data will be used to compare with the scientific finds gained from our HIV positive participants. Also you involvement in this study will provide you will knowledge of how HIV affects your own body through acquiring knowledge of you internal, gynecological and physical health. That's why every WIHS participant is so important. About WIHS The Women's Interagency HIV Study, WIHS, began in 1993 to ...
http://assistive.usablenet.com/tt/uab.edu/medicine/wihs/
*  Is Itchy Skin A Sign Of Acute HIV Infection - The Body
. Is Itchy Skin A Sign Of Acute HIV Infection - The Body. Skip to main content. Skip page links. TOPICS IN HIV/AIDS. Ask The Experts. Search. Search. Follow Us. Facebook. Twitter. Newsletters. Search. Search. THEBODY.COM. What's New Newsletters Android/iPhone App My Health Tracker Personal Reminder Service HIV Care Professionals The Body en Espanol ASOFinder.com. Ask The Experts. TOPICS IN HIV/AIDS. Treatment. HIV Medications. Hepatitis C Coinfection. GI Issues. Other Side Effects Coinfections. Drug Resistance. Switching Stopping Treatment. Pediatric HIV Treatment. Prevention. HIV/AID Basics. HIV Prevention. HIV Testing. Safer Sex. Other Sexually Transmitted Diseases. Myths About HIV/AIDS. History of the AIDS Epidemic. Immune System Basics. Helping Friends With HIV/AIDS. Living With HIV. Getting Good Care. Healthy Living With HIV. Arts, Media HIV/AIDS. Diet, Nutrition HIV/AIDS. HIV Stigma. ...
http://thebody.com/h/is-itchy-skin-a-sign-of-acute-HIV-infection.html
*  Infectious Disease Clinic | Stanford Health Care
Infectious Disease Clinic. Stanford Health Care. For Health Care Professionals. Stanford Health Care SHC formerly Stanford Hospital & Clinics. Infectious Disease Clinic. Infectious Disease Clinic. Our team of infectious disease doctors have specialized expertise in many areas, including: General infectious diseases Infections related to immunodeficiency Travel medicine and tropical diseases HIV and sexually transmitted diseases Bone and joint infections Infections associated with cystic fibrosis. Montoya, Infectious disease doctor, Infectious disease doctor. Care and Treatment of Infectious Diseases. Stanford Health Care's infectious diseases clinics provide state-to-the-art diagnosis and treatment for patients with various kinds of infections. We have over 10 clinic doctors with highly specialized expertise at the following Bay Area clinics: General Infectious Diseases Clinic Treats infections of different etiologies and of different organ systems, from bacterial pneumonia, Clostridium difficile ...
https://stanfordhealthcare.org/medical-clinics/infectious-disease-clinic.html
*  HPV in Adolescents - Full Text View - ClinicalTrials.gov
Sponsor: The HIV Netherlands Australia Thailand Research Collaboration Collaborators: Thai Red Cross AIDS Research Centre Chulalongkorn University South East Asia Research Collaboration with Hawaii We Understand Group TREAT Asia Information provided by Responsible Party : The HIV Netherlands Australia Thailand Research Collaboration. This study will assess the prevalence of HPV infection in perinatally HIV-infected adolescents, intraepithelial neoplasia, and E6E7 biomarker at cervical and anal sites. Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:. Primary Outcome Measures: HPV infection Prevalence of cervical and anal HPV infection and of oncogenic subtypes, among perinatally HIV-infected adolescents, behaviorally HIV-infected adolescents, and HIv-negative adolescents. Perinatally HIV-infected adolescents Perinatally HIV-infected adolescents. behaviorally HIV-infected adolescents ...
https://clinicaltrials.gov/show/NCT01788852?order=233
*  Reducing the HIV infection rate
Re: Reducing the HIV infection rate Reply #100 on: December 04, 2008, 07:34:59 PM. Logged Aug 07 Diagnosed Oct 07 CD4=446 19% Feb 08 CD4=421 19% Jun 08 CD4=325 22% Jul 08 CD4=301 18% Sep 08 CD4=257/VL=75,000 Oct 08 CD4=347 16% Dec 08 CD4=270 16% Jan 09 CD4=246 13% /VL=10,000 Feb 09 CD4=233 15% /VL=13,000 Started meds Sustiva/Epzicom May 09 CD4=333 24% /VL=650 Aug 09 CD4=346 24% /VL=UD Nov 09 CD4=437 26% /VL=UD Feb 10 CD4=471 31% /VL=UD June 10 CD4=517 28% /VL=UD Sept 10 CD4=687 31% /VL=UD Jan 11 CD4=557 30% /VL=UD April 11 CD4=569 32% /VL=UD Switched to Epizcom, Reyataz and Norvir Interrupted for 2 months with only Epizcom Reyataz July 11 CD=520 28% /VL=UD Oct 11 CD=771 31% /VL=UD 30 April 12 CD=609 28% /VL=UD 20 Aug 12 CD=657 29% /VL=UD 20 Dec 12 CD=532 31% /VL=UD 20 May 13 CD=567 31% /VL=UD 20 Jan 14 CD=521 21% /VL=UD 50. Re: Reducing the HIV infection rate Reply #102 on: December 05, 2008, 02:49:11 PM. Re: Reducing the HIV infection rate Reply #103 on: December 05, 2008, 03:54:59 PM. ...
http://forums.poz.com/index.php?topic=24430.msg309779
*  Effectiveness of Antiretroviral Therapy During Acute HIV Infection - Full Text View - ClinicalTrials
Primary Outcome Measures: Difference in the level of HIV RNA at viral load set point if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment. Secondary Outcome Measures: Difference in the level of CD4 cells if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment Difference in the level of HIV RNA and CD4 cell numbers between therapy initiated during acute HIV infection followed by terminal treatment interruption after at least 12 weeks of treatment and no therapy at 16 weeks after discontinuation of treatment Difference in the level of HIV at viral load set point and CD4 cell number at 72 weeks after study entry if therapy is initiated during acute HIV infection followed by terminal treatment interruption at 12 weeks versus at 32 weeks. Drug: ...
https://clinicaltrials.gov/show/NCT00705926?order=31
*  WHO | HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing da
WHO. HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Skip to main content. Access. Home Alt+0. Navigation Alt+1. Content Alt+2. Search. Search the WHO .int site. Submit. Advanced search. Navigation. Home. Health topics. Data. Media centre. Publications. Countries. Programmes. Governance. About WHO. Language. عربي. 中文. English. Français. Русский. Español. RSS Feed. Youtube. Twitter. Facebook. Google +. iTunes. Play Store. Bulletin of the World Health Organization. Menu. Bulletin. Past issues. Information for contributors. Editorial members. How to order. About the Bulletin. Disclaimer. . HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Joel Negin & Robert G Cumming. Objective. To quantify the number of cases and prevalence of human immunodeficiency virus HIV infection among older adults in sub-Saharan Africa. Methods. We reviewed data from Demographic and Health Surveys DHS. Although in ...
http://who.int/bulletin/volumes/88/11/10-076349-ab/en/
*  hivandhepatitis.com - HIV Treatment | HIV Clinical Trials
hivandhepatitis.com - HIV Treatment. hivandhepatitis.com. Facebook. Contact Us. Get in touch Contact Us. Content Past Conferences. Conference Coverage. HIV/AIDS HIV/AIDS Topics HIV Prevention. HIV Disease Progression. HIV Populations. HIV Treatment. HIV Testing Diagnosis. HIV-Related Conditions. Hepatitis B Hepatitis B Topics HBV Treatment. HBV Disease Progression. HBV Populations. HBV Prevention. HBV Testing Diagnosis. Hepatitis C. HIV/Hepatitis Coinfection HIV/HBV Coinfection. HIV/HCV Coinfection. Other Health News Other Health News Topics Influenza. XMRV, MLV Other Retroviruses. HIV/AIDS HIV/AIDS Topics HIV Treatment. HIV Topics. HIV Disease Progression. HIV/AIDS Epidemiology. HIV Populations. HIV Treatment. Approved HIV Drugs. Experimental HIV Drugs. Treatment Guidelines. HIV Prevention. Treatment as Prevention. HIV Testing ...
http://hivandhepatitis.org/hiv-aids/hiv-aids-topics/hiv-treatment/271,278-hiv-clinical-trials-hiv-clinical-trials/3418-counting-your-chickens-reliance-on-unreliable-information-about-medical-studies
*  Clinical and Laboratory Monitoring of Pediatric HIV Infection | Pediatric ARV Guidelines | AIDSinfo
Clinical and Laboratory Monitoring of Pediatric HIV Infection. Please send your comments with the subject line Comments on Pediatric ARV Guidelines to ContactUs@aidsinfo.nih.gov by March 20, 2015. CD4 cell count/percentage and plasma HIV RNA viral load should be measured at the time of diagnosis of HIV infection and at least every 3 to 4 months thereafter for children not on combination antiretroviral therapy cART AIII. After initiation of cART or after a change in cART regimen, children should be evaluated for clinical side effects and to support treatment adherence within 1 to 2 weeks, with laboratory testing for toxicity and viral load response recommended at 2 to 4 weeks after treatment initiation AIII. 12,14 Plasma viral load 100,000 copies/mL in older children also has been associated with high risk of disease progression and mortality, particularly if CD4 percentage is 15% see Table C in Appendix C: Supplemental Information. Monitoring of Children Receiving Antiretroviral Therapy ...
https://aidsinfo.nih.gov/guidelines/html/2/pediatric-treatment-guideline/59/laboratory-monitoring-of-pediatric-hiv-infection-before-initiation-of--therapy
*  Human immunodeficiency virus infection among tuberculosis patients in Mumbai Sawant SS, Agrawal SR,
... Shastri JS, Pawaskar M, Kadam P - J Lab Physicians. Human immunodeficiency virus infection among tuberculosis patients in Mumbai Sandhya S Sawant, Sachee R Agrawal, Jayanthi S Shastri, Medha Pawaskar, Pradeep Kadam Department of Microbiology, B.Y.L. Aim: To determine the seroprevalence of HIV infection among TB confirmed patients in a tertiary care center in Mumbai in view of the significance of HIV in TB. Keywords: Human immunodeficiency virus, seroprevalence, Tuberculosis. How to cite this article: Sawant SS, Agrawal SR, Shastri JS, Pawaskar M, Kadam P. Human immunodeficiency virus infection among tuberculosis patients in Mumbai. How to cite this URL: Sawant SS, Agrawal SR, Shastri JS, Pawaskar M, Kadam P. Human immunodeficiency virus infection among tuberculosis patients in Mumbai. Our laboratory caters laboratory services to all such patients, and tests are carried out as per the guidelines laid down by the National AIDS Control Organization NACO, India. There were more patients in the ...
http://jlponline.org/article.asp?issn=0974-2727;year=2011;volume=3;issue=1;spage=12;epage=14;aulast=Sawant
*  Acute HIV Infection Observational Study - Full Text View - ClinicalTrials.gov
... Sponsor: National Institute of Allergy and Infectious Diseases NIAID Information provided by Responsible Party : National Institute of Allergy and Infectious Diseases NIAID. The purpose of this study is to collect data and body fluid samples from people with acute or established HIV infection and from HIV uninfected people. HIV Infections. Further study details as provided by National Institute of Allergy and Infectious Diseases NIAID :. 2 Established HIV-infection. One system using such strategies has already been implemented in North Carolina, and this system will be used in this study run by the Center of HIV/AIDS Vaccine Immunology CHAVI. The study will enroll HIV infected people with acute HIV infection and their sexual partners, people with established HIV infection, and HIV uninfected people. Group 1 participants will be people with acute HIV infection. Group 2 participants will be people with established HIV infection. ...
https://clinicaltrials.gov/show/NCT00296660?order=61
*  Phys.org - hiv transmission(... continued page 2)
Phys.org - hiv transmission ... Home hiv transmission. News tagged with hiv transmission. 1 week. 1 week. 1 week. hiv · hiv infection · aids. Adult circumcision has been proposed as a possible HIV prevention strategy for gay men, but a new study by the University of Pittsburgh Graduate School of Public Health presented at the XVIII International AIDS Conference ... Jul 22, 2010 in HIV & AIDS. The BC Centre of Excellence in HIV/AIDS BC-CfE published an important study today in the globally respected Lancet medical journal. The study strongly reinforces the view that the benefits of highly active antiretroviral ... Jul 19, 2010 in HIV & AIDS. Introduction of highly active antiretroviral treatment for HIV patients has halved new HIV diagnoses since 1996. A Canadian study being presented at the forthcoming International AIDS Society IAS conference shows that the annual number of new HIV diagnoses has more than halved since the ...
http://phys.org/tags/hiv transmission/sort/rank/all/page2.html
*  "MEN ON FILM: How Media Depictions of Black MSM Impact HIV Infection Rates" - CHIPTS | Center for HI
men on film how media depictions of black msm impact hiv infection rates chipts center for hiv identification prevention and treatment services home news about affiliated organizations aids research centers community advisory board contact us cores directions history mission scientific advisory board welcome people cab members researchers projects resources hiv implementation science behavioral economics hiv intervention research clinical trial of prep in l a funding opportunities links intervention manuals nih publication compliance policy briefs surveys scales youtube events archived events upcoming events eztel conference room calendar blog get involved donate employment join a study volunteering events men on film how media depictions of black msm impact hiv infection rates men on film how media depictions of black msm impact hiv infection rates loading map west hollywood city council chambers n san vicente blvd west hollywood details date time date s dec ...
http://chipts.ucla.edu/events/men-film-media-depictions-black-msm-impact-hiv-infection-rates/
*  IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfect
... ed Children and Adolescents - Full Text View - ClinicalTrials.gov. IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents This study is enrolling participants by invitation only. Official Title: IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents. Methylphenidate Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows: Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant prescribed efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a prescribed protease inhibitor PI * with concomitant ritonavir at boosting doses or lopinavir/ritonavir. Amphetamine / dextroamphetamine Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows: Stratum A - 15 HIV ...
https://clinicaltrials.gov/show/NCT01232361?order=121
*  BMC Pediatrics | Abstract | A retrospective study of Human Immunodeficiency Virus transmission, mort
bmc pediatrics abstract a retrospective study of human immunodeficiency virus transmission mortality and loss to follow up among infants in the first months of life in a prevention of mother to child transmission programme in an urban hospital in kwazulu natal south africa biomedcentral com bmcpediatr article bottom top biomed central journals gateways search bmc pediatrics biomed central for go advanced search home articles authors reviewers about this journal my bmc pediatrics bmc pediatrics infection volume viewing options abstract full text pdf kb additional files associated material pubmed record article metrics open badges readers comments pre publication history related literature cited by google blog search other articles by authors on google scholar chetty t knight s giddy j crankshaw tl butler lm newell ml on pubmed chetty t knight s giddy j crankshaw tl butler lm newell ml related articles pages on google on google scholar on pubmed tools download references download xml order reprints post a ...
http://biomedcentral.com/1471-2431/12/146/abstract
*  Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large c
... ross-sectional study of HIV-infected patients on antiretroviral therapy - Gianotti - 2012 - HIV Medicine - Wiley Online Library. Skip to Main Content. Log in / Register. Log In. E-Mail Address. Password. Forgotten Password. Remember Me. Register. Institutional Login. Home. Microbiology Virology. Infectious Disease. HIV Medicine. Vol 14 Issue 3. Abstract. JOURNAL TOOLS Get New Content Alerts. Get RSS feed. Save to My Profile. Get Sample Copy. Recommend to Your Librarian. JOURNAL MENU Journal Home FIND ISSUES Current Issue. All Issues FIND ARTICLES Early View. Most Accessed. Most Cited. GET ACCESS Subscribe / Renew. FOR CONTRIBUTORS OnlineOpen. Author Guidelines. Submit an Article. ABOUT THIS JOURNAL Society Information. News. Overview. Editorial Board. Permissions. Advertise. Contact. SPECIAL FEATURES Wiley's Infectious Disease Collection. Follow us on Twitter. Free Guidelines. Wiley Job Network. Jobs. Original research You have free access to this content Number of daily pills, ...
http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1293.2012.01046.x/abstract
*  Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: Secondary analyses of
... pooled community based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa ALPHA - ResearchGate. Article Effect of HIV infection on pregnancy-related mortality in sub-Saharan Africa: Secondary analyses of pooled community based data from the network for Analysing Longitudinal Population-based HIV/AIDS data on Africa ALPHA. We used longitudinal data from the Analysing Longitudinal Population-based HIV/AIDS data on Africa ALPHA network to estimate the excess mortality associated with HIV during pregnancy and the post-partum period in sub-Saharan Africa. Mean prevalence of HIV infection across all person-years in the pooled data was 17 2% 95% CI 17 0-17 3, but 60 of 118 50 8% of the women of known HIV status who died during pregnancy or post partum were HIV infected. We used longitudinal data from the Analysing Longitudinal Population-based HIV/AIDS data on Africa ALPHA network to estimate the excess ...
http://researchgate.net/publication/236918075_Effect_of_HIV_infection_on_pregnancy-related_mortality_in_sub-Saharan_Africa_Secondary_analyses_of_pooled_community_based_data_from_the_network_for_Analysing_Longitudinal_Population-based_HIVAIDS_data_on_Africa_(ALPHA)
*  Pharmaceutical Companies Working to Develop CCR5 Inhibitor Drugs to Treat HIV Infection - TheBody.co
... m. Medical News Pharmaceutical Companies Working to Develop CCR5 Inhibitor Drugs to Treat HIV Infection From Henry J. Kaiser Family Foundation. February 18, 2005 Several pharmaceutical companies are "racing" to bring to market a new class of antiretroviral drugs, called CCR5 inhibitors, that would prevent HIV from entering human cells rather than fighting the virus once it has entered cells, Reuters reports Hirschler, Reuters, 2/16. The Pfizer compound has entered Phase III trials Kaiser Daily HIV/AIDS Report, 1/6. Graeme Moyle, an HIV expert at the Chelsea and Westminster Hospital in London, said, "We need these drugs," adding, "We have downsides with the medications we have at present in terms of toxicity, in terms of patient adherence and in terms of the management of virus resistance, which makes the need for new drug classes absolutely critical." The experimental drugs are expected to be discussed at the 12th Conference on Retroviruses and Opportunistic Infections next ...
http://thebody.com/content/art9274.html
*  HIV Tests Cost, How much Do HIV Tests Cost
... HIV Symptoms. HIV Tests Cost HIV human immunodeficiency virus leads to develop AIDS. This virus attacks on the CD4 cells that are known to be the soldier cells in human body. It replicates itself and eventually overcomes the CD4 cells and immune system succumbs to develop AIDS. There are various HIV tests available for detecting the existence of HIV in human body. However, HIV tests cost differs from test to test. Various tests and their cost are given below : Rapid HIV tests A rapid HIV test is a screening test that offers very quick results, normally in five to thirty minutes. Single Use Diagnostic System is the rapid test that is approved by FDA in USA. What is the cost of a rapid HIV test. Does the rapid HIV test cost more than the EIA. Single Use Diagnostic System SUDS test kit normally costs $6to $10. The individual kit of rapid test is more expensive than the EIA test. Hospital cost for HIV tests A screening test for ...
http://hivsymptomsonline.com/hiv-test-cost.html
*  Body Shape Changes Research: 2004 - TheBody.com
In The XV International AIDS Conference On TheBodyPRO.com A HAART Regimen With Lower Metabolic Effect: Nevirapine Plus Non-Thymidine Analog NRTIs July 14, 2004 In The XV International AIDS Conference , from TheBodyPRO.com Kidney Fat Could Be a Predictor of Lipodystrophy July 6, 2004 Researchers use ultrasound to gauge the likelihood a patient will develop lipodystrophy after starting HAART, or whether a treatment switch will improve existing lipodystrophy. From aidsmap.com On TheBodyPRO.com Vitamins and Exercise May Help HIV-Related Metabolic Disorders June 19, 2004 In The Advocate Vitamins, Exercise May Help Metabolic Disorders June 16, 2004 In CDC HIV/Hepatitis/STD/TB Prevention News Update , from CDC National Prevention Information Network Lipid-Lowering Drug Helps Triglyceride Levels in HIVers With Lipodystrophy June 2004 A daily dose of fenofibrate is found to lower abnormally high triglyceride levels in HIV-positive people with lipodystrophy, without causing any severe side ...
http://thebody.com/index/subtopic/lipo_res_2004.html
*  Psychological Issues in Patients With Primary HIV Infection - TheBodyPRO.com
... Get Email Updates Patients Visit TheBody.com. Print-Friendly. Wrap-Up Psychological Issues in Patients With Primary HIV Infection. From The Center for AIDS. In particular, depression is the most common psychiatric disorder among HIV-infected patients and pharmacological intervention may be warranted. Persons diagnosed with primary HIV infection PHI are faced with psychological challenges unique to their early disease stage. A PHI patient presenting with symptoms such as fevers, rash, or diarrhea may confuse these symptoms with those of AIDS. Patients with PHI should first be assured that they do not have AIDS and that PHI is an early disease stage after which many people remain healthy for 10 years or longer, even without treatment. Of equal concern, especially if the clinician decides to initiate antiretroviral therapy during PHI, is that patients understand why they will be taking potent drugs to fight HIV when most chronically infected people are advised to wait until mid- ...
http://thebodypro.com/content/art16815.html
*  Connecting Lower HIV Infection Rates with Changes in Sexual Behaviour in Thailand - Data collection
connecting lower hiv infection rates with changes in sexual behaviour in thailand data collection and comparison unaids p home help preferences search titles subjects organizations expand text expand contents detach no highlighting connecting lower hiv infection rates with changes in sexual behaviour in thailand data collection and comparison unaids p introduction introduction hiv in thailand the early days epidemiological information behavioural information linking epidemiological patterns with behaviour keeping track of a dynamic epidemic conclusion
http://nzdl.org/gsdlmod?e=d-00000-00---off-0unaids--00-0----0-10-0---0---0direct-10---4-------0-1l--11-en-50---20-preferences---00-0-1-00-0--4----0-0-11-10-0utfZz-8-00&a=d&c=unaids&cl=CL1.1&d=HASH0196a4d22e0be33e37d419ae
*  NEUROCOGNITIVE PROBLEM RATE LOW WITH EARLY HIV DIAGNOSIS IN US
... POZ Community Forums. NEUROCOGNITIVE PROBLEM RATE LOW WITH EARLY HIV DIAGNOSIS IN US. Meds, Mind, Body Benefits Questions About Treatment Side Effects Insurance, Benefits Programs HIV Mental Health HIV Lipodystrophy Metabolic Problems Nutrition HIV Research News Studies. Author Topic: NEUROCOGNITIVE PROBLEM RATE LOW WITH EARLY HIV DIAGNOSIS IN US Read 857 times. NEUROCOGNITIVE PROBLEM RATE LOW WITH EARLY HIV DIAGNOSIS IN US on: March 03, 2013, 06:44:38 AM. NEUROCOGNITIVE PROBLEM RATE LOW WITH EARLY HIV DIAGNOSIS IN US http://www.iasociety.org/Default.aspx?pageId=5 elementId=15025 ic=700100 Author: Mark Mascolini 22 February 2013 US military beneficiaries diagnosed with HIV and cared for early in the course of infection had a neurocognitive impairment rate similar to that of a matched group of military beneficiaries without HIV. The findings suggest that early HIV diagnosis and management may forestall development of neurocognitive ...
http://forums.poz.com/index.php?topic=47637.0
*  .. New Study of HIV Hot Spots
← Intratumor Heterogeneity aka, Things Have Many Parts Avastin for Lung Cancer →. New Study of HIV Hot Spots By Jessica Wapner Posted: March 14, 2012. HIV infection rates of black women in certain parts of the United States is five times higher than the overall rate of infection among black women, according to a newly published study by the HIV Prevention Trials Network HPTN. The study, HPTN 064, looked at HIV rates in six geographic “hot spots”; that is, regions of the U.S. known to have elevated rates of HIV and poverty. HPTN 064 also called “The Women’s HIV SeroIncidence Study, which somehow qualifies for the questionable acronym “ISIS” enrolled women ages 18 to 44 without a prior positive HIV test. Among the 2,099 women enrolled in the study, 88% of whom were black, the HIV incidence was 0.24%. As a measure of comparison, here is a char t showing HIV/AIDS rates in sub-Saharan Africa, though note that the rates show HIV/AIDS, not ...
http://blogs.plos.org/workinprogress/2012/03/14/new-study-of-hiv-hot-spots/
*  Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults - Full
Safety of and Immune System Response to an HIV Vaccine EP HIV-1090 in HIV Uninfected Adults - Full Text View - ClinicalTrials.gov. Safety of and Immune System Response to an HIV Vaccine EP HIV-1090 in HIV Uninfected Adults This study has been completed. Sponsor: National Institute of Allergy and Infectious Diseases NIAID Information provided by Responsible Party : National Institute of Allergy and Infectious Diseases NIAID. The purpose of this study is to test the safety of an HIV DNA vaccine EP HIV-1090 and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people. Further study details as provided by National Institute of Allergy and Infectious Diseases NIAID :. Criteria Inclusion Criteria HIV negative Positive for one or more of the following HLA supertypes: -A2, -A3, or -B7 Willing to receive HIV test results Good general health Acceptable methods of contraception for females of ...
https://clinicaltrials.gov/ct2/show/study/NCT00054860?view=results
*  Gender Difference in Mucosal Integrity Impacts Response to HAART in HIV Infection
... 19th Conference on Retroviruses and Opportunistic Infections Seattle, WA March 5 - 8, 2012. Gender Difference in Mucosal Integrity Impacts Response to HAART in HIV Infection. Women have higher levels of T cell activation at all stages of HIV infection and during HAART. These preliminary data suggest that increased microbial translocation may explain why women have sustained CD4+T-cell activation despite effective viral suppression. The increased microbial translocation could be the result of decreased or ineffective tight junction formation or increased disruption of the tight junctions due to a combination of infection and hormonal factors. HIV infection results in loss of CD4+ T-cells in Gut- Associated Lymphoid Tissue GALT and in compromised gut epithelial integrity. HIV disease progression correlates with immune activation, which is higher in women compared to men. HIV positive women on HAART have higher levels of T-cell activation than HIV positive men on ...
http://natap.org/2012/CROI/croi_118.htm
*  Ziagen User Reviews for HIV Infection at Drugs.com
... Search:. All Consumer Professional Pill ID Interactions News FDA Alerts Approvals Pipeline Clinical Trials Care Notes Encyclopedia Dictionary Natural Products. Advanced Search. Sign In. Sign In. Sign In. Drugs A-Z. Drugs by Condition. Drugs by Class. Generic Drugs. OTC Drugs. Natural Products. Pregnancy Warnings. Advanced Search. News. Apps. Drugs A to Z. Ziagen. User Reviews. User Reviews for Ziagen The following information is NOT intended to endorse drugs or recommend therapy. Learn more about Ziagen. Reviews for Ziagen to treat HIV Infection No reviews have yet been submitted. Learn more about HIV Infection Micromedex Care Notes: Aids. Aids, Ambulatory Care. Hiv Infection. Sexually Transmitted Diseases. Sexually Transmitted Diseases In Adolescents. Sexually Transmitted Diseases In Adolescents, Ambulatory Care. Sexually Transmitted Diseases, Ambulatory Care Symptoms and treatment for: HIV/AIDS Drugs.com Health Center: AIDS / HIV. Treating AIDS & HIV. AIDS / ...
http://drugs.com/comments/abacavir/ziagen-for-hiv-infection.html
*  Bureau of HIV, STD, and Hepatitis - HIV/AIDS Program
... Home. A-Z Index. What We Do. News. Calendar. Employment. Definitions. Contact Us. Take Our Survey. County Public Health Contacts. HIV / AIDS Program Home. HIV Community Planning Group. Prevention Program. HIV/AIDS: Resources & Links. Care & Support Services. Data & Statistics. HIV/AIDS Program. STD Program. Hepatitis Program HIV Prevention Program The HIV/AIDS Program receives HIV prevention funds from the Centers for Disease Control and Prevention CDC to provide for HIV counseling and testing, partner counseling and referral services, health education/risk reduction activities and health communication/public information activities. These activities are targeted to high-risk individuals as defined in Iowa’s HIV Prevention Comprehensive Plan. The funding is also awarded to support HIV prevention community planning, technical assistance and capacity building activities. Online Resource Directory for Gay/Bi/Trans Men in Iowa ...
http://idph.state.ia.us/HivStdHep/HIV-AIDS.aspx?prog=Hiv&pg=HivPrev
*  Effective HIV care benefited all HIV patients, regardless of demographics and behavioral risk
... HIV/AIDS What Is AIDS. AIDS/HIV Symptoms Symptoms and phases AIDS HIV Prevention AIDS HIV Detection Transmission of HIV Sexual acts Transmission Acute HIV infection What causes AIDS HIV / AIDS FAQ Early hiv symptoms HIV and AIDS Symptoms Myths about HIV transmission Basic management and monitoring I'm HIV positive AIDS/HIV Detection & Treatment Immunotherapy for HIV Infection HIV and Hepatitis C in prisons. Introduction to HIV Immunology Related to AIDS The impact of HIV and AIDS Biology of Human Immunodeficiency Viruses Epidemiology of HIV infection Prevention of HIV infection Neurologic Complications of HIV-1 Infection Pulmonary Manifestations of HIV Infection. Gastrointestinal Manifestations of AIDS Cutaneous Signs of AIDS Ophthalmologic Manifestations of AIDS Hematology/Oncology in AIDS Renal, Cardiac, Endocrine, and Rheumatologic Manifestations of HIV ...
http://health.am/aids/more/effective-hiv-care-benefited-all-hiv-patients/
*  University of Pennsylvania HIV Prevention Research Division | The Fix
University of Pennsylvania HIV Prevention Research Division. Skip to main content Search form Search Search. NEWS FEATURES BLOGS LIVING SOBER ASK AN EXPERT PRO VOICES QUIZZES ABOUT US. Trending Rehab Reviews Treatment Centers Resources. Will My Insurance Pay for Rehab. Rehab Directory Cash Pay Treatment for VIPS and Execs How to Choose the Best Rehab Interventionists Sober Livings Pain Management Mental Health Buprenorphine doctors Rehab Detox Insurance. NEWS FEATURES BLOGS LIVING SOBER ASK AN EXPERT PRO VOICES QUIZZES ABOUT US. This is an advertisement and the insurance benefit check is a service performed by one of The Fix’s advertising sponsors. This is an advertisement and the insurance benefit check is a service performed by one of The Fix’s advertising sponsors. This is an advertisement and the insurance benefit check is a service performed by one of The Fix’s advertising sponsors. Trending Rehab Reviews Treatment Centers Resources. Will My Insurance Pay for Rehab. Rehab Directory Cash Pay ...
https://thefix.com/tags/university-pennsylvania-hiv-prevention-research-division
*  AIDSinfo At-a-Glance | Issue No. 9 | March 02, 2012
FDA Issues Safety Announcement About Interactions Between Certain HIV or Hepatitis C Drugs and Cholesterol-Lowering Statin Drugs The U.S. Food and Drug Administration FDA is issuing updated recommendations concerning drug-drug interactions between drugs for human immunodeficiency virus HIV or hepatitis C virus HCV known as protease inhibitors and certain cholesterol-lowering drugs known as statins. The labels for both the HIV protease inhibitors and the affected statins have been updated to contain consistent information about the drug-drug interactions. Study Examines Effect of HIV Infection, Immunodeficiency, and Antiretroviral Therapy on the Risk of Hepatic Dysfunction Limited data exists regarding the effect of chronic HIV infection on the liver. We sought to characterize the hepatic risks of HIV infection, immunodeficiency and cumulative use of antiretroviral therapy ART. Adult HIV-infected and 10:1 age- and sex-matched HIV-uninfected individuals ...
https://aidsinfo.nih.gov/e-news/archive/2012/3/2
*  Phys.org - hiv transmission(... continued page 3)
Phys.org - hiv transmission ... Home hiv transmission. News tagged with hiv transmission. 1 week. 1 week. 1 week. hiv · hiv infection · aids. Some HPV infection may be linked to increased risk of HIV acquisition in women. PhysOrg.com -- UCSF researchers have found a novel association between human papillomavirus HPV infection and increased HIV acquisition in women. Expansion of HIV screening cost-effective in reducing spread of AIDS, Stanford study shows. program of HIV screening and treatment could prevent as many as 212,000 new infections over the next 20 years and prove to be very cost-effective, according to a new study by Stanford University School of ... Study examines risk of heterosexual HIV transmission in China. 6-month drug regimen cuts HIV risk for breastfeeding infants. Giving breastfeeding infants of HIV-infected mothers a daily dose of the antiretroviral drug nevirapine for six months halved the risk of ...
http://phys.org/tags/hiv transmission/sort/popular/all/page3.html
*  Study Suggests Immune Systems of Untreated HIV-Infected Individuals May Deteriorate Faster Than Prev
... iously Thought - TheBodyPRO.com. Press Release Study Suggests Immune Systems of Untreated HIV-Infected Individuals May Deteriorate Faster Than Previously Thought. National Institute of Allergy and Infectious Diseases. July 29, 2009 The immune systems of untreated HIV-infected individuals appear to deteriorate faster than previously thought, according to preliminary results of a small clinical trial. Known as the SETPOINT study, or A5217, the trial was designed to compare the point at which the amount of HIV in the blood levels off in two groups of people with recent HIV infection: those who receive a 36-week course of antiretroviral therapy ART , and those who receive no therapy until they meet immunologic, virologic or clinical criteria for starting ART. Since it is commonly thought that people with untreated HIV infection lose approximately 60 CD4+ T cells/mm 3 per year, and since U.S. Advertisement The SETPOINT study has been conducted by the Acute Infection and ...
http://thebodypro.com/content/art53110.html?nxtprv
*  Rural counties experience funding and stigma problems in HIV prevention services | AHRQ Archive
Rural counties experience funding and stigma problems in HIV prevention services. AHRQ Archive. www.ahrq.gov AHRQ Home—Live Site. Please go to www.ahrq.gov for current information. HIV/AIDS Research Rural counties experience funding and stigma problems in HIV prevention services. Healthcare 411. Rural counties experience funding and stigma problems in HIV prevention services Research Activities, January 2011, No. 365 As local HIV prevention agencies fight growing rates of HIV infection, they have fewer and fewer resources, making it difficult for them to maintain existing programs and services, as well as launch new programs. Over 400 informants were asked about performance of county health services, HIV prevention activities, community attitudes, and community cooperation and collaboration. Agency representatives at 169 agencies were asked to evaluate how well their agency performed on HIV prevention-related services, such as accessibility and ...
http://archive.ahrq.gov/news/newsletters/research-activities/jan11/0111RA21.html
*  .. HIV/AIDS Treatment as Prevention strategy working in B.C. Montaner calls for national implementa
Email. HIV/AIDS Treatment as Prevention strategy working in B.C. Montaner calls for national implementation. Media Release. November 27, 2012. A new study from the BC Centre for Excellence in HIV/AIDS BC-CfE shows highly active antiretroviral therapy HAART reduces new HIV diagnoses, deaths and HIV prevalence, suggesting that the made-in-Canada Treatment as Prevention strategy should be implemented across the country. The study, published today in the online journal PLOS One, investigated patterns of new HIV diagnoses, HIV-related mortality and HAART use in Canada from 1995 to 2008. Analysis showed that for each 10 per cent increment in HAART coverage, the rate of new HIV diagnoses decreased by eight per cent in B.C., Ontario and Quebec — three provinces with the largest epidemics. In B.C., the Treatment as Prevention strategy has led to the widespread expansion of HAART coverage. The total number of new HIV diagnoses in the province dropped during the ...
http://news.ubc.ca/2012/11/27/ubc-study-reinforces-need-for-national-implementation-of-treatment-as-prevention-strategy-to-save-lives-fight-hivaids/
*  HOME | hivandhepatitis.com
HIV Disease Progression. HIV Testing Diagnosis. HBV Disease Progression. HBV Prevention. HBV Testing Diagnosis. HIV/Hepatitis Coinfection HIV/HBV Coinfection. HIV/HCV Coinfection. HIVandHepatitis.com coverage of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention IAS 2015 , July 19-22, in Vancouver, Canada. Coverage of the 2015 EASL International Liver Congress. HIVandHepatitis.com coverage of the 50th European Association for the Study of the Liver International Liver Congress EASL 2015 in Vienna, April 22-26, 2015. Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV antivirals, hepatitis B and delta, and management of liver disease complications. Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections. HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections CROI 2015 , February ...
http://hivandhepatitis.com/recent/2008/101408_c.html
*  Burlington NC Infectious Disease Specialist Doctors - Tularemia: Learn About Symptoms and Treatment
Bell University Of North Carolina Infectious Diseases Clinic 101 Manning Dr Chapel Hill, NC 27514 919 966-2536 1 office location s. Sparling University Of North Carolina Infectious Diseases Clinic 101 Manning Dr Chapel Hill, NC 27514 919 966-2536 1 office location s. Weber University Of North Carolina Infectious Diseases Clinic 101 Manning Dr Chapel Hill, NC 27514 919 966-2536 2 office location s. Gay University Of North Carolina Infectious Diseases Clinic 101 Manning Dr Chapel Hill, NC 27514 919 966-2536 1 office location s. Patterson University Of North Carolina Infectious Diseases Clinic 101 Manning Dr Chapel Hill, NC 27514 919 966-2536 1 office location s. Barroso Wake Forest Baptist Health Outpatient Infectious Disease Clinic Medical Center Blvd Winston-Salem, NC 27157 336 716-4395 1 office location s. Peacock Wake Forest Baptist Health Outpatient Infectious Disease Clinic Medical Center Blvd Winston-Salem, NC 27157 336 716-4395 1 office location s. Schafer Wake Forest Baptist Health Outpatient ...
http://medicinenet.com/tularemia/burlington-nc_city.htm
*  Prevention of Parent to Child Transmission - Overview of HIV/AIDS in India
... HIV/AIDS What Is AIDS. AIDS/HIV Symptoms Symptoms and phases AIDS HIV Prevention AIDS HIV Detection Transmission of HIV Sexual acts Transmission Acute HIV infection What causes AIDS HIV / AIDS FAQ Early hiv symptoms HIV and AIDS Symptoms Myths about HIV transmission Basic management and monitoring I'm HIV positive AIDS/HIV Detection & Treatment Immunotherapy for HIV Infection HIV and Hepatitis C in prisons. Introduction to HIV Immunology Related to AIDS The impact of HIV and AIDS Biology of Human Immunodeficiency Viruses Epidemiology of HIV infection Prevention of HIV infection Neurologic Complications of HIV-1 Infection Pulmonary Manifestations of HIV Infection. Gastrointestinal Manifestations of AIDS Cutaneous Signs of AIDS Ophthalmologic Manifestations of AIDS Hematology/Oncology in AIDS Renal, Cardiac, Endocrine, and Rheumatologic Manifestations of HIV ...
http://health.am/aids/more/prevention-of-parent-to-child-transmission/
*  National HIV/AIDS Clinicians' Consultation Center
... 'National HIV/AIDS Clinicians' Consultation Center NCCC ' is a free expert clinical consultation service for healthcare providers seeking consultation on HIV / AIDS and management of potential exposures to HIV, hepatitis, and other blood-borne pathogens. http://www.cdc.gov/hiv/topics/basic/index.htm#history Healthcare professionals who frequently use the Warmline, PEPline, and Perinatal HIV Hotline include physicians, nurses, physician assistants, pharmacists, dentists, and other allied health professionals seeking expert consultation. 'The Warmline' 'National HIV Telephone Consultation Service' 1-800-933-3413 is a clinical consultation service that provides free advice from HIV expert clinicians on HIV/AIDS management and prevention of transmission. 'The PEPline' 'National Clinicians’ Post-Exposure Prophylaxis Hotline' 1-888-448-4911 provides around-the-clock expert guidance on managing healthcare worker exposures to HIV and hepatitis B and ...
https://en.wikipedia.org/wiki/National_HIV/AIDS_Clinicians'_Consultation_Center
*  Medical Xpress - hiv infection rates
... Home hiv infection rates. News tagged with hiv infection rates. sort by:. Date. 6 hours. 12 hours. 1 day. 3 days. all. Rank. Last day. 1 week. 1 month. all. LiveRank. Last day. 1 week. 1 month. all. Popular. Last day. 1 week. 1 month. all. Sorry, no news articles match your request. Your search criteria may be too narrow. Subscribe to rss feed. Topics. Addiction. Alzheimer's disease & dementia. Arthritis & Rheumatism. Attention deficit disorders. Autism spectrum disorders. Cancer. Cardiology. Dentistry. Diabetes. Diseases, Conditions, Syndromes. Genetics. Health. HIV & AIDS. Immunology. Inflammatory disorders. Medical research. Medications. Neuroscience. Obstetrics & gynaecology. Ophthalmology. Other. Overweight and Obesity. Parkinson's & Movement disorders. Pediatrics. Psychology & Psychiatry. Sleep apnea. Surgery. Conditions. Asthma. Breast cancer. Cardiovascular disease. Chronic obstructive pulmonary disease. Colon cancer. Coronary artery disease. Dementia. Depression. Heart ...
http://medicalxpress.com/tags/hiv infection rates/sort/liverank/1d/
*  Publications: Moore, Corey - Murdoch Research Repository
... Publications: Moore, Corey. Stats for Moore, Corey. , Moore, C. , Mallal, S. , St John, M.A. , Moore, C. , Mallal, S. , Allen, T.M. , Walker, B.D. and Brander, C. , Nolan, D. , James, I. , Gaudieri, S. , Moore, C. and Mallal, S. Journal of Virology, 80 18. Gaudieri, S. , Lucas, M. , Moore, C. 2005 Adaptation of Hepatitis C virus to HLA-restricted responses in an Australian host population. 2005 Adaptation of Hepatitis C virus to HLA-restricted responses in an Australian host population. 2004 Adaptation of Hepatitis C virus to HLA-restricted responses in HLA diverse populations. 2004 Adaptation of hepatitis C virus to HLA-restricted responses in HLA diverse populations. 2003 HIV adaptation to HLA-restricted immune responses - implications for vaccine design and evaluation. In: 10th Conference on Retroviruses and Opportunistic Infections, 10 - 14 February 2003, Boston, U.S.A. 2002 Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level. Moore, Corey Benjamin ...
http://researchrepository.murdoch.edu.au/view/author/Moore, Corey.date.html
*  Benefits and Risks of Early Antiretroviral Therapy for HIV | Health Encyclopedia | Keene | Dartmouth
Benefits and Risks of Early Antiretroviral Therapy for HIV. Health Encyclopedia. Keene. Dartmouth-Hitchcock. Dartmouth-Hitchcock. Contact Us. Site Map. Cheshire Medical Center/Dartmouth-Hitchcock Keene. Patients & Visitors. Clinical Care. Health & Wellness. Healthy Monadnock. Careers. Health Encyclopedia. Health & Wellness. Health Encyclopedia. Benefits and Risks of Early Antiretroviral Therapy for HIV. Medical experts recommend that people begin treatment for HIV as soon as they know that they are infected. 2 Treatment is especially important for pregnant women, people who have other infections such as tuberculosis or hepatitis, and people who have symptoms of AIDS. Benefits and risks of antiretroviral therapy for HIV. Early therapy : Treatment with antiretroviral medicines as soon as HIV is diagnosed. Delayed therapy : Treatment with antiretroviral medicines some time after HIV is diagnosed. Benefits. Even with early therapy, the risk of HIV transmission ...
http://cheshire-med.com/health_wellness/health_encyclopedia/aa5845
*  Thomas R Fleming
Publications Current issues in non-inferiority trials Thomas R Fleming Department of Biostatistics, University of Washington, Seattle, WA 98195, USA Stat Med 27:317-32. 2005 Some design issues in trials of microbicides for the prevention of HIV infection Thomas R Fleming Department of Biostatistics, University of Washington, Seattle, Washington 98195, USA J Infect Dis 190:666-74. Research Grants HIV PREVENTION TRIALS NETWORK LEADERSHIP GROUP Thomas Fleming; Fiscal Year: 2005 STATISTICAL ISSUES IN AIDS RESEARCH Thomas Fleming; Fiscal Year: 2007 Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials Network Thomas Fleming; Fiscal Year: 2007 CLINICAL RESEARCH ON AIDS TRAINING GRANT Thomas Fleming; Fiscal Year: 2007. Some design issues in trials of microbicides for the prevention of HIV infection Thomas R Fleming Department of Biostatistics, University of Washington, Seattle, Washington 98195, USA J Infect Dis 190:666-74. Some essential considerations in the ...
http://labome.org/expert/usa/university/fleming/thomas-r-fleming-226403.html
*  hivandhepatitis.com - Gilead Requests FDA Approval of Truvada for HIV Prevention | HIV Prevention
hivandhepatitis.com - Gilead Requests FDA Approval of Truvada for HIV Prevention. HIV/AIDS HIV/AIDS Topics HIV Prevention. HIV Disease Progression. Hepatitis B Hepatitis B Topics HBV Treatment. HBV Disease Progression. HBV Prevention. HBV Testing Diagnosis. HIV/AIDS HIV/AIDS Topics. HIV Prevention Gilead Requests FDA Approval of Truvada for HIV Prevention. Gilead Requests FDA Approval of Truvada for HIV Prevention Details Category: HIV Prevention. Gilead Sciences announced this week that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration FDA requesting approval of a new indication for Truvada, its tenofovir/emtricitabine combination pill, for HIV pre-exposure prophylaxis PrEP. As described this summer at the International AIDS Society conference in Rome, the iPrEx study of gay men and the Partners PrEP and TDF2 trials of heterosexual men and women showed that once-daily ...
http://hivandhepatitis.net/hiv-aids/hiv-aids-topics/hiv-prevention/3394-gilead-requests-fda-approval-of-truvada-for-hiv-prevention
*  World AIDS Day -- December 1, 1996
... Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation in the subject line of e-mail. World AIDS Day -- December 1, 1996 One World, One Hope is the theme designated by the Joint United Nations Programme on HIV/AIDS UNAIDS for this year's World AIDS Day, December 1, 1996. Worldwide, 190 countries observe World AIDS Day to focus attention on the human immunodeficiency virus HIV /acquired immunodeficiency syndrome AIDS pandemic, which has resulted in an estimated 27.9 million HIV infections and 5.8 million deaths, including 1.3 million deaths in children 1,2. In the United States, activities for World AIDS Day are coordinated by the American Association for World Health in collaboration with UNAIDS, the Pan American Heath Organization, and the U.S. Department of Health and Human Services. Additional information about HIV infection, AIDS, and World AIDS Day is ...
http://cdc.gov/mmwr/preview/mmwrhtml/00044513.htm
*  Probable Acquisition of Multi-Drug-Resistant HIV in Man With Subsequent Rapid HIV Disease Progressio
The Body Covers: The 12th Conference on Retroviruses and Opportunistic Infections Probable Acquisition of Multi-Drug-Resistant HIV in Man With Subsequent Rapid HIV Disease Progression: Reality and Reaction Coverage provided by David A. Beyond the hype, this case report raises serious questions regarding the relationship between transmission of drug-resistant virus and rapid HIV disease progression, as well as the adequacy of HIV prevention efforts. During this special session, data from 2 large cohort studies of individuals at risk for HIV infection, the Multicenter AIDS Cohort Study MACS and the Women's Interagency HIV Study WIHS, and a cohort of recently infected military personnel were reviewed with respect to the variability of the pace of HIV progression following acquisition of the virus. Abstract: Introductory Remarks and Summary of Case Report of Recent Infection by a Multi-Drug Resistant, Dual-Tropic HIV-1 in Association with Rapid Progression ...
http://thebody.com/content/art14848.html?nxtprv
*  Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for ea
... rly infant diagnosis in high HIV prevalence settings. University of California, San Francisco. Comprehensive, up-to-date information on HIV/AIDS treatment, prevention, and policy from the University of California San Francisco. Universal HIV Testing. Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in high HIV prevalence settings. Universal HIV testing of infants at immunization clinics: an acceptable and feasible approach for early infant diagnosis in high HIV prevalence settings. In Context The World Health Organization WHO recommends early initiation of antiretroviral therapy ART in HIV-infected infants. 4 Objective To determine the acceptability and feasibility of HIV testing of infants presenting for immunization Setting Three primary care clinics in KwaZulu Natal, South Africa Study Design Non-randomized, single-arm intervention Participants Infants attending any of ...
http://hivinsite.ucsf.edu/InSite?page=jl-58-04
*  hivandhepatitis.com - AIDS 2012: Switching from Protease Inhibitor to Complera Maintains Viral Suppr
... ession, Lowers Lipids. HIV/AIDS HIV/AIDS Topics HIV Prevention. HIV Disease Progression. Hepatitis B Hepatitis B Topics HBV Treatment. HBV Disease Progression. HBV Testing Diagnosis. HIV/Hepatitis Coinfection HIV/HBV Coinfection. Approved HIV Drugs AIDS 2012: Switching from Protease Inhibitor to Complera Maintains Viral Suppression, Lowers Lipids. AIDS 2012: Switching from Protease Inhibitor to Complera Maintains Viral Suppression, Lowers Lipids Details Category: Approved HIV Drugs. People who switched to the all-in-one Complera rilpivirine/tenofovir/emtricitabine combination pill from a boosted protease inhibitor continued to have undetectable viral load and on average had improved lipid profiles associated with lower cardiovascular risk, according to study findings presented at the XIX International AIDS Conference AIDS 2012 last week in Washington, DC. Results Switching to Complera was found to be non-inferior to staying on a ritonavir-boosted ...
http://hivandhepatitis.com/hiv-treatment/approved-hiv-drugs/3713-aids-2012-switching-from-protease-inhibitor-to-complera-maintains-viral-suppression-lowers-lipids
*  Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth - Full Text View - ClinicalT
... rials.gov. Skip to Main Content. A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies:. Advanced Search. Help. Studies by Topic. Glossary. Find Studies. Basic Search. Advanced Search. See Studies by Topic. See Studies on Map. How to Search. How to Use Search Results. How to Find Results of Studies. How to Read a Study Record. About Clinical Studies. Learn About Clinical Studies. Other Sites About Clinical Studies. Glossary of Common Site Terms. Submit Studies. Why Should I Register and Submit Results. FDAAA 801 Requirements. How to Apply for an Account. How to Register Your Study. How to Edit Your Study Record. How to Submit Your Results. Frequently Asked Questions. Support Materials. Training Materials. Resources. Selected Publications. Clinical Alerts and Advisories. RSS Feeds. Trends, Charts, and Maps. Downloading Content for Analysis. About This Site. ClinicalTrials.gov Background. About the Results Database. History, Policies, and Laws. ...
https://clinicaltrials.gov/ct2/show/study/NCT00102960?view=record
*  Special Medical Reports: Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infec
... ted with HIV - American Family Physician. Advertisement. Previous article Next article. Jul 1, 1998 Issue. Special Medical Reports Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV. FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access. FREE PREVIEW. Purchase online access to read the full version of this article. VERNA ROSE Am Fam Physician. 1998 Jul 1;58 1 :261-263. The Public Health Service has updated the 1994 guidelines for the use of zidovudine Retrovir to reduce the risk for perinatal transmission of human immunodeficiency virus HIV. The new report is intended to help health care professionals educate pregnant women with HIV infection about the use of zidovudine and other antiretroviral drugs during pregnancy. The report was published in the January 30, 1998, issue of Morbidity and Mortality Weekly Report recommendations and reports series MMWR Morb Mortal Wkly Rep 1998; ...
http://aafp.org/afp/1998/0701/p261.html
*  Initiating Antiretroviral Therapy in Treatment-Naive Patients | Adult and Adolescent ARV Guidelines
Search HIV/AIDS Drugs. Antiretroviral therapy ART is recommended for all HIV-infected individuals to reduce the risk of disease progression. Benefits of Antiretroviral Therapy Reduction in Mortality and/or AIDS-Related Morbidity According to Pretreatment CD4 Cell Count Patients with a History of an AIDS-Defining Illness or CD4 Count 350 cells/mm3 HIV-infected patients with CD4 counts 200 cells/mm 3 are at higher risk of opportunistic diseases, non-AIDS morbidity, and death than HIV-infected patients with higher CD4 counts. 16 The study estimated that delaying initiation of ART until CD4 count fell to 350 cells/mm 3 was associated with a greater risk of AIDS-defining illness or death than initiating ART with CD4 count between 350 cells/mm 3 and 500 cells/mm 3 HR: 1.38; 95% CI, 1.23 1.56. 18 In contrast, in an analysis of the ART-CC cohort, 13 the rate of progression to AIDS/death associated with deferral of therapy until CD4 counts fell to the 351 to 450 cells/mm 3 range was ...
https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/10/initiating-antiretroviral-therapy-in-treatment-naive-patients
*  Re: HIV infection from dried blood? - TheBody.com's Bulletin Boards
Re: HIV infection from dried blood. - TheBody.com's Bulletin Boards. HIV Life >> Living With HIV. Re: HIV infection from dried blood. If pimple is not considered an open sore or lesion, can I take this as a true fact that even when blood containing active HIV virus contacted with this unbroken pimple, I would not be infected by HIV either. HIV infection from dried blood. Re: HIV infection from dried blood. Re: HIV infection from dried blood. Re: HIV infection from dried blood. another question on toilet panic05 06/21/05 11:25 PM. Re: another question on toilet Anonymous 06/25/05 04:15 PM. Re: another question on toilet panic05 06/25/05 07:56 PM. Re: another question on toilet debtex 06/22/05 12:28 AM. Re: another question on toilet Anonymous 06/23/05 11:24 PM. Re: another question on toilet searching 06/23/05 11:43 PM. Re: HIV infection from dried blood. Re: HIV infection from dried blood. Re: HIV infection from dried ...
http://thebody.com/cgi-bin/bbs/showthreaded.php?Cat=&Board=living&Number=156324
*  A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to
... Treatment - Tabular View - ClinicalTrials.gov. A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment This study has been completed. Sponsor: University of Chicago Collaborator: Abbott Information provided by Responsible Party : David Pitrak, University of Chicago. Current Primary Outcome Measures ICMJE submitted: August 23, 2013. Current Secondary Outcome Measures ICMJE submitted: August 23, 2013. Rates of ex Vivo T Cell Apoptosis: CD4+ Memory Cell Population Ex vivo T cell apoptosis can be assessed many different ways. Rates of ex Vivo T Cell Apoptosis: CD4+ na ve Cell Population Ex vivo T cell apoptosis can be assessed many different ways. 1 Rates of ex vivo T cell apoptosis, CD4+, CD8+, both memory and na ve cell populations, 2. Current Other Outcome Measures ICMJE. A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment. Randomized Trial of a Switch to a Kaletra + Current Dual ...
https://clinicaltrials.gov/ct2/show/record/NCT00145795
*  President Obama’s mixed record on HIV/AIDS | New Pittsburgh Courier
President Obama’s mixed record on HIV/AIDS. New Pittsburgh Courier. Opinion President Obama’s mixed record on HIV/AIDS. President Obama’s mixed record on HIV/AIDS. NNPA VIENNA—Unlike any president before him, President Barack Obama has announced a national HIV/AIDS strategy, something AIDS activists had been demanding for more than a decade. president—George W. The centerpiece of the campaign is a composite photo—one half of the face of Bush merged with half of Obama’s face—with the inscription: “Who’s Better on AIDS?”. Phill Wilson, president and CEO of the Black AIDS Institute, the only African-American think tank on HIV/AIDS, believes Obama is far better than Bush on policy issues, including fulfilling his campaign pledge to create an HIV/AIDS national strategy. He said the president will be ultimately judged on whether he and other leaders reduce the HIV infection rates, especially among African-Americans. Although Blacks are only 12.8 percent of the U.S., ...
http://newpittsburghcourieronline.com/2010/07/21/president-obamas-mixed-record-on-hivaids/
*  "Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth
... Conference Reports for NATAP. 20th Conference on Retroviruses and Opportunistic Infections Atlanta, GA March 3 - 6, 2013. Back  . "Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth. . 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta Mark Mascolini An HIV-infected US infant treated from 31 hour after birth had no detectable viral load, no detectable HIV DNA in blood cells, and no HIV-specific antibodies at 26 months of age on standard tests, even though antiretroviral therapy ART stopped at age 18 months. Deborah Persaud Johns Hopkins University and colleagues believe their findings confirm "a state of functional HIV cure." Speedy treatment after birth appeared to work like postexposure prophylaxis PEP, stopping HIV from getting a foothold in this baby's body and establishing a latent viral reservoir. Evidence that the baby was infected persisted, however, in vanishingly small levels of HIV RNA ...
http://natap.org/2013/CROI/croi_08.htm
*  Two immune proteins found to control HIV infection...
... POZ 100. ABOUT HIV/AIDS. What is HIV/AIDS. POZ Community Forums. Meds, Mind, Body Benefits. Two immune proteins found to control HIV infection... Meds, Mind, Body Benefits Questions About Treatment Side Effects Insurance, Benefits Programs HIV Mental Health HIV Lipodystrophy Metabolic Problems Nutrition HIV Research News Studies. Off Topic Forums Off Topic Forum Forums Gatherings. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums. Author Topic: Two immune proteins found to control HIV infection... Two immune proteins found to control HIV infection... Two immune proteins found to control HIV infection by Alan McCord, January 9, 2009. The NIAID research used new technology to watch how CD8s interact with CD4 cells that are infected with HIV in both LTNPs and progressors whose HIV levels were comparably under control below 50 with drugs. In turn, certain CD8s carry out the task of killing ...
http://forums.poz.com/index.php?topic=25553.msg319517
*  Study Finds HIV Infection Is an Independent Risk Factor for Lung Cancer - TheBodyPRO.com
... Study Finds HIV Infection Is an Independent Risk Factor for Lung Cancer By Warren Tong. May 24, 2012 Simply having HIV is an independent risk factor for lung cancer, according to a recent study from the U.S. They compiled data from 32,794 HIV-infected individuals and 75,750 HIV-uninfected individuals. There were 457 new cases of lung cancer in the HIV-infected group an incidence rate of 1.4% , compared with 614 cases in the HIV-uninfected group an incidence rate of 0.8%. Advertisement After controlling for other risk factors, the researchers calculated the incidence rates in terms of number of person-years at risk. They found that the incidence rate of lung cancer in the HIV-infected group was 204 cases per 100,000 person-years, while the rate for the HIV-uninfected control group was 119 cases per 100,000 person-years. Which means about a 71% higher rate of lung cancer in the HIV-positive group. The percentage of current smokers between the ...
http://thebodypro.com/content/67293/study-finds-hiv-infection-is-an-independent-risk-f.html
*  Matched case–control study to evaluate risk factors for hyperlactataemia in HIV patients on antire
Matched case control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy - Datta - 2003 - HIV Medicine - Wiley Online Library. HIV Medicine. JOURNAL MENU Journal Home FIND ISSUES Current Issue. All Issues FIND ARTICLES Early View. Wiley Job Network. You have free access to this content Matched case control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. D Datta, G Moyle, S Mandalia and B Gazzard Article first published online: 3 OCT 2003 DOI: 10.1046/j.1468-1293.2003.00164.x. HIV Medicine Volume 4, Issue 4, pages 311 314, October 2003. Additional Information How to Cite Datta, D., Moyle, G., Mandalia, S. 2003, Matched case control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy. HIV Medicine, 4: 311 314. E-mail: dattauk@yahoo.co.uk. Publication History Issue published online: 3 OCT 2003 Article first published online: 3 OCT ...
http://onlinelibrary.wiley.com/doi/10.1046/j.1468-1293.2003.00164.x/abstract
*  The role of cost-effectiveness analysis in assessing HIV-prevention interventions. Building communit
... y and culture are essential to successful HIV prevention for gay and bisexual men. The role of cost-effectiveness analysis in assessing HIV-prevention interventions Article Abstract: Three HIV-prevention interventions are evaluated using simple cost-effectiveness techniques. The main advantage of using cost-effectiveness to assess HIV-prevention strategies is its ability to use data to achieve public health goals. Policy makers can use cost-effectiveness analysis to distribute prevention resources among populations, based on differences in HIV incidence, program costs and effectiveness of interventions. H Publisher: University Publishing Group Publication Name: AIDS & Public Policy Journal Subject: Law ISSN: 0887-3852 Year: 1997. Comment about this article or add new information about this topic: Public Comment:  50-4000 characters. Building community and culture are essential to successful HIV prevention for gay and bisexual men Article Abstract: The main ...
http://readabstracts.com/Law/The-role-of-cost-effectiveness-analysis-in-assessing-HIV-prevention-interventions.html
*  A Wiznia
... add/edit. You are here: Scientific Experts USA Wiznia A Wiznia. Research Topics hiv fusion inhibitors nelfinavir stavudine puerto rico nevirapine ritonavir hiv envelope protein gp41 anti retroviral agents hiv antibodies continental population groups reverse transcriptase inhibitors ethnic groups hiv infections anti hiv agents viral rna peptide fragments combination drug therapy viral load electric impedance body composition cytokines cd4 lymphocyte count anthropometry lipids hiv. A Wiznia Summary Country: USA. Publications Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children Jacobo Abadi Division of Infectious Diseases, Department of Pediatrics, Jacobi Medical Center and Albert Einstein College of Medicine, 1400 Pelham Parkway, Bronx, NY, USA J Acquir Immune Defic Syndr 41:298-303. 2006 Combination nucleoside analog reverse transcriptase inhibitor s plus nevirapine, nelfinavir, ...
http://labome.org/expert/usa/wiznia/a-wiznia-732040.html
*  Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth - No Study Results Posted -
... ClinicalTrials.gov. Skip to Main Content. A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles" Search for studies:. Advanced Search. Help. Studies by Topic. Glossary. Find Studies. Basic Search. Advanced Search. See Studies by Topic. See Studies on Map. How to Search. How to Use Search Results. How to Find Results of Studies. How to Read a Study Record. About Clinical Studies. Learn About Clinical Studies. Other Sites About Clinical Studies. Glossary of Common Site Terms. Submit Studies. Why Should I Register and Submit Results. FDAAA 801 Requirements. How to Apply for an Account. How to Register Your Study. How to Edit Your Study Record. How to Submit Your Results. Frequently Asked Questions. Support Materials. Training Materials. Resources. Selected Publications. Clinical Alerts and Advisories. RSS Feeds. Trends, Charts, and Maps. Downloading Content for Analysis. About This Site. ClinicalTrials.gov Background. About the Results Database. History, Policies, and ...
https://clinicaltrials.gov/ct2/show/results/NCT00102960
*  Asymptomatic HIV infectionAsymptomatic HIV infection
 Asymptomatic HIV infection. Asymptomatic HIV infection. Main Number: 314-434-1500. Emergency Dept: 314-205-6990. Patient Billing: 888-924-9200. Home. About Us. Services. Patients & Visitors. Health Tools. Classes & Events. Donate & Volunteer. Physicians & Employees. Careers. Contact Us History Mission Locations & Directions Quality Reports Annual Reports Honors & Awards Community Health Needs Assessment Newsroom Brain & Spine Cancer Heart Maternity Orthopedics Pulmonary Sleep Medicine Urgent Care Women's Services All Services Locations & Directions Find a Physician Tour St. Luke's Patient & Visitor Information Contact Us Payment Options Financial Assistance Send a Card Mammogram Appointments My Personal Health. my stlukes. Spirit of Women Health Information & Tools Clinical Trials Health Risk Assessments Employer Programs - Passport to Wellness Classes & Events Spirit of Women Giving Opportunities Volunteer For Physicians Remote Access Medical Residency Information Pharmacy Residency ...
http://stlukes-stl.com/health-content/mens/2/9500.htm

HIV-positive people: HIV-positive people are people who have the human immunodeficiency virus HIV, the agent of the currently incurable disease AIDS.Management of HIV/AIDS: The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs in an attempt to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle.QRISK: QRISK2 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial fibrillation, diabetes mellitus, and antihypertensive treatment.Seroprevalence: Seroprevalence is the number of persons in a population who test positive for a specific disease based on serology (blood serum) specimens; often presented as a percent of the total specimens tested or as a proportion per 100,000 persons tested. As positively identifying the occurrence of disease is usually based upon the presence of antibodies for that disease (especially with viral infections such as Herpes Simplex and HIV), this number is not significant if the specificity of the antibody is low.Chlamydophila pneumoniaeCD4 immunoadhesin: CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region.Eva Engvall: Eva Engvall, born 1940, is one of the scientists who invented ELISA in 1971.Eva Engvall, The Scientist 1995, 9(18):8CagA: Helicobacter pylori virulence factor CagA (cytotoxin-associated gene A) is a 120–145kDa protein encoded on the 40kb cag pathogenicity island (PAI). H.Toxocariasis: (ILDS B83.01)Cytomegalic inclusion body disease: Cytomegalic inclusion body disease (CIBD) is a series of signs and symptoms caused by cytomegalovirus infection, toxoplasmosis or other rare infections such as herpes or rubella viruses. It can produce massive calcification of the central nervous system, and often the kidneys.Adult-onset immunodeficiency syndrome: Adult-onset immunodeficiency syndrome is a provisional name for a newly diagnosed immunodeficiency illness. The name is proposed in the first public study to identify the syndrome.Vpx: Vpx is a virion-associated protein encoded by human immunodeficiency virus type 2 HIV-2 and most simian immunodeficiency virus (SIV) strains, but that is absent from HIV-1. It is similar in structure to the protein Vpr that is carried by SIV and HIV-2 as well as HIV-1.World Blood Donor Day: Every year on 14 June, countries around the world celebrate World Blood Donor Day (WBDD). The event, established in 2004, serves to raise awareness of the need for safe blood and blood products, and to thank blood donors for their voluntary, life-saving gifts of blood.List of people with hepatitis C: The infectious disease hepatitis C is caused by the hepatitis C virus (HCV), which affects the liver and is transmitted by blood-to-blood contact, or by exposure to another person's infected blood. The infection is often asymptomatic, but chronic infection can cause inflammation of the liver (chronic hepatitis).Nested case-control study: A nested case control (NCC) study is a variation of a case-control study in which only a subset of controls from the cohort are compared to the incident cases. In a case-cohort study, all incident cases in the cohort are compared to a random subset of participants who do not develop the disease of interest.History of syphilis: The history of syphilis has been well studied, but the exact origin of syphilis is unknown. There are two primary hypotheses: one proposes that syphilis was carried to Europe from the Americas by the crew of Christopher Columbus, the other proposes that syphilis previously existed in Europe but went unrecognized.RegavirumabSAG1 protein domain: In molecular biology, the SAG1 protein domain is an example of a group of glycosylphosphatidylinositol (GPI)-linked proteins named SRSs (SAG1 related sequence). SAG1 is found on the surface of a protozoan parasite Toxoplasma gondii.University of CampinasPrescott Townsend: Prescott Townsend (June 24, 1894 – May 23, 1973) was an American gay rights activist.

(1/3131) Tuberculous meningitis in South African urban adults.

We retrospectively reviewed 56 adults with culture-proven tuberculous meningitis (TBM), investigating clinical signs, cerebrospinal fluid (CSF) findings and outcome. There were 50 patients, aged 18-59 years, 39 with and 11 without human immunodeficiency virus (HIV) infection. Six were aged 60 years or older. Neurological signs of TBM in 18-59-year-olds were unaffected by HIV serostatus while, compared to those > or = 60 years of age, there were more patients with meningism (86.0% vs. 33.3%; p = 0.011) and fewer with seizures (12.0% vs. 50.0%; p = 0.046). The HIV-infected 18-59-year-olds had significantly more extrameningeal tuberculosis compared to the non-HIV-infected (76.9% vs. 9.1%; p = 0.0001) and 23.1% had 'breakthrough' TBM. CSF analysis revealed 12 patients (21.4%) with acellular fluid (more common in those > or = 60 years of age, p = 0.016), of whom three had completely normal CSF. A neutrophil predominance was found in 22 patients (39.3%). Only three patients (5.4%) had a positive CSF smear for acid-fast bacilli. In-hospital mortality occurred in 39 patients (69.1%), was similar in all study groups, and was not related to neurological stage. The diagnosis of TBM can be masked by lack of meningism in the elderly and by atypical CSF findings.  (+info)

(2/3131) Coalescent estimates of HIV-1 generation time in vivo.

The generation time of HIV Type 1 (HIV-1) in vivo has previously been estimated using a mathematical model of viral dynamics and was found to be on the order of one to two days per generation. Here, we describe a new method based on coalescence theory that allows the estimate of generation times to be derived by using nucleotide sequence data and a reconstructed genealogy of sequences obtained over time. The method is applied to sequences obtained from a long-term nonprogressing individual at five sampling occasions. The estimate of viral generation time using the coalescent method is 1.2 days per generation and is close to that obtained by mathematical modeling (1.8 days per generation), thus strengthening confidence in estimates of a short viral generation time. Apart from the estimation of relevant parameters relating to viral dynamics, coalescent modeling also allows us to simulate the evolutionary behavior of samples of sequences obtained over time.  (+info)

(3/3131) Cytokine profile induced by Cryptosporidium antigen in peripheral blood mononuclear cells from immunocompetent and immunosuppressed persons with cryptosporidiosis.

The proliferative response of peripheral blood mononuclear cells (PBMC) to a crude extract from Cryptosporidium parvum (CCE) was studied in persons who acquired cryptosporidiosis in the same outbreak (15 immunocompetent subjects with prior cryptosporidiosis and 22 human immunodeficiency virus [HIV]-positive persons with various levels of immunosuppression and active cryptosporidiosis) and in individual patients (8 HIV-positive patients with active cryptosporidiosis and 15 HIV-positive persons without history of cryptosporidiosis). PBMC from HIV-positive persons showed less proliferation to CCE and mitogens than did PBMC from immunocompetent subjects with prior cryptosporidiosis, independent of CD4 cell count. In immunocompetent subjects, cytokine gene expression was consistent with cytokine production, whereas in HIV-positive subjects it was not. The production of interferon-gamma in CCE-stimulated PBMC from both immunocompetent and HIV-positive subjects with cryptosporidiosis and the lack of interferon-gamma in CCE-stimulated PBMC from HIV-positive subjects without cryptosporidiosis indicate that C. parvum mainly induces a Th1 response.  (+info)

(4/3131) Cardiac autoimmunity in HIV related heart muscle disease.

OBJECTIVE: To assess the frequency of circulating cardiac specific autoantibodies in HIV positive patients with and without echocardiographic evidence of left ventricular dysfunction. SUBJECTS: 74 HIV positive patients including 28 with echocardiographic evidence of heart muscle disease, 52 HIV negative people at low risk of HIV infection, and 14 HIV negative drug users who had all undergone non-invasive cardiac assessment were studied along with a group of 200 healthy blood donors. RESULTS: Cardiac autoantibodies detected by indirect immunofluorescence (serum dilution 1/10) were more common in the HIV positive patients (15%), particularly the HIV heart muscle disease group (21%), than in HIV negative controls (3.5%) (both p < 0.001). By ELISA (dilution 1/320), abnormal anti-alpha myosin autoantibody concentrations were found more often in HIV patients with heart muscle disease (43%) than in HIV positive patients with normal hearts (19%) or in HIV negative controls (3%) (p < 0.05 and p < 0.001, respectively). Anti-alpha myosin autoantibody concentrations were greater in HIV positive patients than in HIV negative controls, regardless of cardiac status ((mean SD) 0.253 (0.155) v 0.170 (0.076); p = 0.003). In particular the mean antibody concentration was higher in the HIV heart muscle disease patients (0.291 (0.160) v 0.170 (0.076); p = 0.001) than in HIV negative controls. On follow up, six subjects with normal echocardiograms but raised autoantibody concentrations had died after a median of 298 days, three with left ventricular abnormalities at necropsy. This compared with a median survival of 536 days for 21 HIV positive patients with normal cardiological and immunological results. CONCLUSIONS: There is an increased frequency of circulating cardiac specific autoantibodies in HIV positive individuals, particularly those with heart muscle disease. The data support a role for cardiac autoimmunity in the pathogenesis of HIV related heart muscle disease, and suggest that cardiac autoantibodies may be markers of the development of left ventricular dysfunction in HIV positive patients with normal hearts.  (+info)

(5/3131) Voluntary newborn HIV-1 antibody testing: a successful model program for the identification of HIV-1-seropositive infants.

Harlem Hospital in New York City has one of the highest HIV-1 newborn seroprevalence rates in the United States. We report the results of a program introduced in 1993 and designed to identify HIV-1-seropositive (HIV+) newborns at birth. All new mothers, independent of risk, received HIV counseling that emphasized the medical imperative to know the infant's HIV status as well as their own. Consent was obtained to test the infant; discarded cord blood samples were tested by enzyme-linked immunosorbent assay (ELISA), and when positive, Western Blot confirmation. We compared the number of HIV+ infants identified through voluntary testing with the number reported by the anonymous New York State Newborn HIV Seroprevalence Study. In 1993, 97.8% (91 of 93) of the number of HIV+ infants identified by the anonymous testing were identified through voluntary maternal and newborn testing programs. Eighty-five HIV+ infants were identified before nursery discharge: 50% (42/85) through newborn testing; 14% (12/85) through prenatal testing; 13% (11/85) presented to care knowing their status; 23% (20/85) were known because of a previous HIV+ child. Six additional HIV+ children were diagnosed after hospital discharge (mean age, 5.5 months; range 1.5 through 17 months); four presented with symptomatic disease. The optimal time for identification of the HIV+ pregnant woman is before or during pregnancy, but when this does not occur, voluntary newborn testing can identify many HIV+ infants who would otherwise be discharged undiagnosed from the nursery.  (+info)

(6/3131) Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure.

A new test that measures interferon-gamma (IFN-gamma) release in whole blood following stimulation with tuberculin has the potential to detect tuberculosis infection using a single blood draw. The IFN-gamma release assay was compared with the standard tuberculin skin test (TST) among 467 intravenous drug users at risk for tuberculosis in urban Baltimore. Among 300 human immunodeficiency virus (HIV)-seronegative patients, the IFN-gamma release assay was positive in 177 (59%), whereas the TST was positive in 71 (24%), for a percent agreement of 59% (kappa=26%). Among 167 HIV-seropositive subjects, the IFN-gamma release assay identified 32 reactors (19%); the TST identified 16 reactors (9.6%), for a percent agreement of 82% (kappa=28%). The IFN-gamma release assay detected more reactors than did the TST, but its agreement with TST was weak. As the TST is an imperfect standard, further evaluation of the IFN-gamma release assay among uninfected persons and persons with culture-confirmed tuberculosis will be useful.  (+info)

(7/3131) Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts.

To assess possible differences in immune status, proportions and absolute numbers of subsets of CD4+ and CD8+ T cells were compared between HIV- healthy Ethiopians (n = 52) and HIV- Dutch (n = 60). Both proportions and absolute numbers of naive CD4+ and CD8+ T cells were found to be significantly reduced in HIV Ethiopians compared with HIV- Dutch subjects. Also, both proportions and absolute numbers of the effector CD8+ T cell population as well as the CD4+CD45RA-CD27- and CD8+CD45RA-CD27- T cell populations were increased in Ethiopians. Finally, both proportions and absolute numbers of CD4+ and CD8+ T cells expressing CD28 were significantly reduced in Ethiopians versus Dutch. In addition, the possible association between the described subsets and HIV status was studied by comparing the above 52 HIV- individuals with 32 HIV+ Ethiopians with CD4 counts > 200/microliter and/or no AIDS-defining conditions and 39 HIV+ Ethiopians with CD4 counts < 200/microliter or with AIDS-defining conditions. There was a gradual increase of activated CD4+ and CD8+ T cells, a decrease of CD8+ T cells expressing CD28 and a decrease of effector CD8+ T cells when moving from HIV- to AIDS. Furthermore, a decrease of naive CD8+ T cells and an increase of memory CD8+ T cells in AIDS patients were observed. These results suggest a generally and persistently activated immune system in HIV- Ethiopians. The potential consequences of this are discussed, in relation to HIV infection.  (+info)

(8/3131) Tissue specific HPV expression and downregulation of local immune responses in condylomas from HIV seropositive individuals.

OBJECTIVE: To study the effect of tissue specific human papillomavirus (HPV) expression and its effect on local immunity in condylomas from HIV positive individuals. METHODS: Biopsy specimens of eight penile and eight perianal condylomas from HIV seropositive individuals were analysed. Expression of viral genes (HIV-tat and HPV E7 and L1) was determined by RT-PCR. The status of local immunity also was determined by RT-PCR by measuring CD4, CD8, CD16, CD1a, HLA-DR, and HLA-B7 mRNA levels in the tissues. Differentiation was determined by measuring involucrin, keratinocyte transglutaminase, as well as cytokeratins 10, 16, and 17. Proliferation markers such as PCNA and c-myc were also determined. RESULTS: The transcription pattern of HPV in perianal condylomas, which preferentially expressed the early (E7) gene, was different from that of penile condylomas, which primarily expressed the late (L1) gene. This transcription pattern is in good correlation with the keratinisation and differentiation patterns of the two epithelia: perianal biopsies preferentially expressed K16 and K17 while penile warts mainly expressed K10, markers of parakeratotic and orthokeratotic epithelia, respectively. Perianal biopsies also showed a higher degree of proliferation (PCNA and c-myc). Interestingly, transcription of HIV-tat was also higher in perianal than in penile biopsies. A high degree of local immunodeficiency was observed in perianal biopsies--that is, levels of CD4, CD16, and CD1a mRNAs were significantly lower. A negative correlation between CD1a (Langerhans cells) levels and HPV E7 levels was established. HPV E7 levels positively correlated with HIV-tat levels. Perianal tissues demonstrated more CD1a depression and tat associated HPV upregulation. CONCLUSION: HIV influences the expression of HPV genes resulting in local immunosuppression that might lead to an inappropriate immune surveillance of viral infection. Also, tissue type is an important factor in controlling viral transcription in a differentiation dependent manner. These findings may explain the higher rate of dysplasia and neoplasia in the perianal area.  (+info)


How long does HIV live in semen and is dried positive semen still infectious?


Does anyone know how long the HIV virus can live in semen and still be able to infect a person? If the semen is HIV positive, but dried, say on a carpet, a couch's upholstery or a piece of paper, can someone still be infected by it? If the dried semen gets wet, is it possible for any virus to be re-animated and be infectious again?

Please let me know, any knowledge would greatly be appreciated.

Thanks!
----------

It is not possible to be infected this way.  Once HIV is outside the body, exposed to air, it only survives for a few minutes.  Once any fluids containing the virus are dried, the virus is already dead.  Making it wet again will not make it infectious again.

(The reason that blood in syringes, whether fresh or dried, continues to be infectious is that the syringe is an airtight environment in which the virus can survive for longer periods of time.)


How long does HIV live in semen and is dried positive semen still infectious?


Hey guys have a question for you. Does anyone know how long HIV-positive semen is still infectious in a dried state? 

Say, as a hypothetical, there was dried HIV-positive semen on upholstery and it has gone uncleaned with any disinfection products. How long would it have had to dry and the virus die for someone with an open wound to come in contact with that upholstery and there be no risk of infection?

 Any help would be greatly appreciated!
----------

the HIV virus dies as soon as it comes in contact with oxygen

and michael has no idea what he's talking about


How long does HIV live in semen and is dried positive semen still infectious?


Hey guys have a question for you. Does anyone know how long HIV-positive semen is still infectious in a dried state?

Say, as a hypothetical, there was dried HIV-positive semen on upholstery and it has gone uncleaned with any disinfection products. How long would it have had to dry and the virus die for someone with an open wound to come in contact with that upholstery and there be no risk of infection?

Any help would be greatly appreciated!
----------

Once outside the body, exposed to air, HIV is only infectious for a few minutes.  If semen is dried, it is no longer infectious.


How hard is it to contract HIV from a person getting treatment and they are at undetectable levels?


We discovered my wife has HIV 6 months and we were having unprotected sex for a year.  I got tested several times and still came up negative.  She had a count of around 80,000 copies per ml of blood.  She is now at undetectable levels meaning she might be less than 100 copies per ml of blood.  What are my chances of contacting from her if we start having unprotected sex again?
----------

We can't even try to guess at the risk. Having a low viral load means that the blood that was tested showed low levels. 

Be mindful that semen levels are never measured in routine follow up. 

Measuring viral load in blood is common, semen-not so. If you're getting information that semen levels and blood levels translate exactly, I'd be wary. As a health care professional who's worked in the HIV field for years-I KNOW THAT SEMEN LEVELS ARE NOT ROUTINELY TESTED, therefore, comparing the levels is not possible.

When a HIV positive person is ill, say for instance from the FLU and viral load is tested-more virus is detected in the blood at that time. That some may be the FLU virus is not determined-only viruses are counted. 

This is all to say that the viral load is a good diagnostic test-to place where one may be in the progression of the disease. It's not to determine the risk of exposure-especially repeated exposure. 

There is no way to determine WHEN the H I Viruses migrate to certain parts of the body. We do know that HIV is harbored and may replicate in body organs.

Unfortunately, unprotected sex should not be an option in even a loving relationship. There's already risk there, decrease it rather than increase it.


What's the difference between people with HIV and people with AIDS?


An HIV+ person told me that the media are still prejudiced against HIV and that, first of all, everyone is being referred to as patients with AIDS; there are no patients with HIV and patients with AIDS and that this is the first thing he observes to be reproduced continuously by the media.

What did he meant by that?
----------

With current Antiretroviral therapy for HIV, if caught EARLY, they can stop the disease progressing to AIDS. Medically, AIDS is no longer used - instead it's called late/end-stage HIV infection (for unimaginate reasons I assume). 

Late-stage HIV infection is when you develop one or more of the 26 late-stage/AIDS infections, for example Kaposi's Sarcoma, Bronhciopneumonia etc.

With today's treatment, if diagnosed at 20 you can live into your 70s. HIV treatment continues to improve year on year.


How was HIV/AIDS discovered and when was the first patient was prognosticated?


HIV/AIDS is the disease which is affecting the world so much; especially the African countries. More people are dying each and everyday; a lot of orphans suffering without assistance. We need to join together and fight this disease.
----------

about 25 years ago. Strange that you ask this question since there was a special covering it on FRONTLINE. You can watch it online here: http://www.pbs.org/wgbh/pages/frontline/aids/view/

It was called Frontline: The Age of AIDS



First known case of human HIV infection
A blood sample is taken in 1959 from a man living in Leopoldville, Belgian Congo, now Kinshasa, Democratic Republic of Congo (formerly Zaire). For decades, the sample is stored away in a freezer. In 1998, after sophisticated testing is developed for HIV, the blood sample from 1959 is tested and confirmed as positive for HIV.

taken from same website - there is actually a time line at this link here:

http://www.pbs.org/wgbh/pages/frontline/aids/cron/crontext.html


How much difference does treatment make for hiv positive people?


I don't have hiv but I have many questions about it as I heard a person on public transit talking about it the other day. 
Btw, 'g' if you answer this I would love to talk to you about a few things if you wouldn't mind?! 
Thanks everyone!
----------

I'm not going to give you a scientific answer but I can tell you what difference it has been on my life. The reason for not giving a science answer is because it can very greatly from person to person with their reaction to the drugs.  What medication they are on and if the strain of HIV has any resistance to the drugs that they are on.  I have been on 2 different cocktail combinations and I'll tell you my experience with both.  I'll give you a before and after from my own experience.

Before any medication
----------------------------------------------------------------------------------------------
Daily headaches that no amount of pain reliever could help with.
Almost daily fevers.  Usually low grade around 100 degrees Fahrenheit.
Thrush - A type of yeast infection in the mouth.
Yeast infections in my arm pits and in my belly button.
Constant fatigue.
I had Phenomia 3 times in 1 year before starting HIV meds.
Night sweats so bad that I would need to change sheets and pillow cases just to have a dry place to sleep.
Constant diarrhea and stomach pains caused by a stomach virus that my body could no fight off no matter what antibiotics I took.
My T-cell (white blood cells that fight off infection) count was only 12.  Normal T-cell count is at least 500 or above, up to 1,300 depending on what test is used.
HIV Viral load at 750,000 (probably higher but the test that was used stopped at 750,000)
Erectile problems.  Not directly related to HIV.  Probably had more to do with the stress I was under from dealing with all of the above.
Severe depression. Probably also from dealing with the above.
Diagnosed with full blown AIDS and not expected to live to leave the hospital. (This is also when I was diagnosed with HIV so had no prior treatment for HIV.)

Remember all of the above was over a course of a year and was pretty much non stop with all of the issues at once. Doctor told me I was probably HIV positive for up to 5 years and didn't know it.

After about 3 months on meds.  (Truvada and Kaletra))
-----------------------------------------------------------------------------------
None of the above problems are present.
Viral load is undetectable.  Undetectable means that your viral load is below 25 to 50 depending on what test is used.
T-cell count is around 350. (Don't remember the exact number) Anything over 300 you are now out of danger from getting phenomia related to HIV as well as thrush and your body can fight off most types of infections.
Depression finally starting to lift.
Erectile function back to normal.
Still having Diarrhea but caused by the meds and not any sickness.

One year later my t-cell count was at 500 and my viral load was till undetectable.

After about a year of being on the above cocktail I asked to change my meds because the Diarrhea from the meds wouldn't go away.  The doctor switched my meds.

Changed to a new cocktail. (Reyataz, Norvir,Truvada)
-----------------------------------------------------------------------------------------
Viral load stays reasonable but hovers at around 1,000 to 3,000 so I sill feel ill some days and have fatigue with some headaches and a small grade fever some days.
White blood cell count goes down to around 400.

This cocktail mix worked okay but not as well as my first cocktail mix so I switched back to my first cocktail mix.

3 years later I am still on the same cocktail mix with a viral load of undetectable. and my T-cell count is at 650. As you can see HIV meds saved my life and I wouldn't be here today without them.  The only time I think about my HIV is when I need to take meds.  No depression related to the HIV at all.  Life is back to normal and I can think about my future and start worrying about retirement.  YAY! As of today I have been on HIV med for 6 years.

Not everyone is so lucky to find a cocktail mix that works for them.  I have known people that spend months or years trying different cocktail combos that work for their HIV.

HIV meds can and do save lives. It pains me that 1,000's of Americans currently do not have access to HIV meds and are slowly dieing an unneeded death as a result. If a doctor has told you or anyone you know that you should start HIV meds you should strongly consider it as it will usually change your life for the better.  HIV meds do take a commitment to take them every day and on time but isn't that worth saving your own life? Nobody is going to make you feel better except you. 

For me it wasn't choice of if I wanted to take meds.  All I had to do was look in the mirror and ask myself "Do you want to live or die?". The answer was very clear to start taking HIV meds.


What are the chances of catching HIV from a woman in Australia?


Hi.

So i am going to make an appointment to get tested for HIV tommorow. I was just wondering what the chances were of catching HIV from a woman in Australia. I understand that it is much more likely from homosexual contact, but can still happen. I had unprotected sex a few times with my then girlfriend over 11 months ago. Thank you all.
----------

HIV does not discriminate. Homosexuality is NOT the only risk factor. Anyone who engages in any type of unprotected sex can become infected with HIV.  Sexual orientation and nationality are irrelevant. Actually, women are infected at a higher rate than homosexual men at this point, although risk of infection through unprotected anal sex is high. 

All of that said, if your last possible exposure was 11 months ago, testing now will give you an accurate result.